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Structure–Activity Relationship Study Reveals ML240 and
ML241 as Potent and Selective Inhibitors of p97 ATPase
Tsui-Fen Chou,*[a, c] Kelin Li,[b] Kevin J. Frankowski,[b] Frank J. Schoenen,[b] and
Raymond J. Deshaies*[a]
Introduction
The hexameric p97 protein belongs to the type II AAA (ATPase
associated with diverse cellular activities) ATPase protein
family and is conserved across all eukaryotes and is essential
for life.[1, 2] p97 is known as VCP (valosin-containing protein) in
mammals and Cdc48p in yeast. p97 plays critical roles in
a broad array of cellular processes including homotypic fusion
of endoplasmic reticulum and Golgi membranes,[3] degradation
of misfolded membrane and secretory proteins,[4] Golgi mem-
brane reassembly,[5] membrane transport,[6] regulation of myofi-
bril assembly,[7] cell division,[8] regulation of protein aggre-
gates,[9] and autophagosome maturation.[10,11] The broad range
of cellular functions for p97 is thought to derive from its ability
to unfold proteins or disassemble protein complexes using the
energy derived from ATP hydrolysis, but the detailed mecha-
nism of how p97 works remains largely elusive.
The mechanochemical activity of p97 is linked to substrate
proteins by a large number of interacting proteins (p97 cofac-
tors) including Npl4 (nuclear protein localization homologue 4),
Ufd1 (ubiquitin fusion degradation 1) heterodimer,[12] and an
array of 13 UBX (ubiquitin regulatory X) domain cofactors.[13]
The physiological functions and mechanisms of action of these
different p97–cofactor complexes remain largely unknown. Our
research group reported a proteomic analysis of UBX cofactors
and revealed their interactions with a large number of E3 ligas-
es.[14] Whereas all UBX proteins interact with p97, only those
containing a ubiquitin associated (UBA) domain associate with
high-molecular-weight ubiquitin conjugates.[14] Thus, some
p97–UBX complexes may have functions that do not involve
polyubiquitination of their substrates. In support of this obser-
vation, Ubxd1, a non-UBA containing UBX protein, associates
with monoubiquitinated caveolin-1 and regulates its endolyso-
somal sorting.[15]
p97 exhibits a tripartite structure, with an N-terminal
domain that recruits cofactor/substrate specificity factors fol-
lowed by two AAA ATPase domains, D1 and D2.[16,17] p97 pro-
tomers assemble to form a homohexamer that is thought to
provide a platform for transduction of chemical energy into
mechanical force, which is then applied to substrate proteins.
The D1 domain mediates hexamerization[18] and has very low
basal ATPase activity.[19] The majority of the ATPase activity de-
To discover more potent p97 inhibitors, we carried out a struc-
ture–activity relationship study of the quinazoline scaffold pre-
viously identified from our HTS campaigns. Two improved in-
hibitors, ML240 and ML241, inhibit p97 ATPase with IC50 values
of 100 nm. Both compounds inhibited degradation of a p97-
dependent but not a p97-independent proteasome substrate
in a dual-reporter cell line. They also impaired the endoplas-
mic-reticulum-associated degradation (ERAD) pathway. Unex-
pectedly, ML240 potently stimulated accumulation of LC3-II
within minutes, inhibited cancer cell growth, and rapidly mobi-
lized the executioner caspases 3 and 7, whereas ML241 did
not. The behavior of ML240 suggests that disruption of the
protein homeostasis function of p97 leads to more rapid acti-
vation of apoptosis than is observed with a proteasome inhibi-
tor. Further characterization revealed that ML240 has broad an-
tiproliferative activity toward the NCI-60 panel of cancer cell
lines, but slightly lower activity toward normal cells. ML240
also synergizes with the proteasome inhibitor MG132 to kill
multiple colon cancer cell lines. Meanwhile, both probes have
low off-target activity toward a panel of protein kinases and
central nervous system targets. Our results nominate ML240 as
a promising starting point for the development of a novel
agent for the chemotherapy of cancer, and provide a rationale
for developing pathway-specific p97 inhibitors.
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and ML241. ODD-Luc degradation western blot assays and aqueous sol-
ubility for select compounds. Table S14 is also provided in Excel format.
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tected in vitro appears to arise from the D2 domain.[20] Interest-
ingly, D1 ATPase mutations affect D2 ATPase activity, and it has
been suggested that a functional D1 domain and positive co-
operativity between the D1 and D2 domains is essential for
cell growth.[21]
We recently reported two high-throughput screening (HTS)
campaigns that yielded a specific small-molecule inhibitor of
p97 ATPase activity, N2,N4-dibenzylquinazoline-2,4-diamine
(DBeQ).[22] DBeQ affects multiple p97-dependent processes in-
cluding ubiquitin fusion degradation (UFD), endoplasmic-retic-
ulum-associated degradation (ERAD), and autophagy. DBeQ
also potently inhibits cancer cell growth. Interestingly, DBeQ
mobilizes the executioner caspases 3 and 7 and induces apop-
tosis more rapidly than the proteasome inhibitor MG132,[22]
thus highlighting p97 as a potentially suitable target for cancer
chemotherapy.
Results and Discussion
SAR for p97 inhibition by 1 and DBeQ
In addition to DBeQ, the HTS screen identified N-benzyl-2-(2-
fluorophenyl)quinazolin-4-amine 1 (Figure 1) as a promising hit
warranting further investiga-
tion.[22] With the aim to discover
more potent p97 inhibitors, we
carried out a structure–activity
relationship (SAR) study of these
two quinazoline hits identified
during the HTS phase
(Figure 2).[22] In total, we exam-
ined 200 analogues with the ma-
jority focused on changes at R1
and R2. R1 replacement afforded
the most dramatic potency
gains, and the benzyl group
from the HTS hits remained the
preferred R2 substitution. Any
substitution for R3 other than hy-
drogen was not well tolerated,
and further analogues were not
explored. Modification to the
core quinazoline scaffold typical-
ly required de novo synthesis of the quinazoline, and although
not exhaustively investigated, alternate core scaffolds and sub-
stituted quinazolines provided a significant boost in potency
when applied to an already potent R1 and R2 combination.
We first purchased analogues of 1, and the activities of
these compounds in the in vitro ATPase and cell-based UbG76V–
GFP degradation assays[23] are shown in full in Supporting In-
formation tables S1 and S2. We began by examining the aro-
matic substitution, with the greatest number of analogues fo-
cused on substitution of the aryl ring at the 2-position of the
quinazoline core. A few analogues exhibited modestly greater
potency in vitro (e.g. compounds 2 and 3, Table 1), but none
of the derivatives performed better than the parent compound
in both the biochemical and cell-based assays. The most dra-
matic effects arose from chloro substitution at the 7-position
on the quinazoline core structure, which caused a 10–23-fold
decrease in biochemical potency (e.g. 4 and 5, Table 1). Replac-
ing the aryl group with a selection of aliphatic heterocycles
consistently decreased activity by 10–20-fold (e.g. 6 and 7,
Table 1). The N-methyl analogue 8 is typical for alkyl-substitut-
ed R3 analogues, possessing potency far below that of the HTS
hit compounds.Figure 1. Structures and p97 inhibitory activities for the HTS hit compounds
1 and DBeQ. IC50 values for inhibition of p97 ATPase activity and degrada-
tion of p97-dependent reporter (UbG76V–GFP) are shown.
Figure 2. Summary of the SAR leading to the discovery of ML240 and
ML241: 200 analogues were tested, mainly exploring changes to R1 and R2.
Table 1. Selected SAR for the initial analogues of the HTS hits 1 and DBeQ.
IC50 [mm]
[a]
Compd R1 R2 R3 R4 ATPase UbG76V–GFP
2 2-chlorophenyl benzyl H H 1.20.6 83
3 3-nitrophenyl benzyl H H 5.93 4.01.6
4 phenyl benzyl H 7-Cl 7024 124
5 p-tolyl benzyl H 7-Cl 3913 245
6 piperidnyl benzyl H H 264 7.32
7 morpholinyl benzyl H H 236 369
8 phenyl benzyl Me H 4917 175
9 N-aminophenyl phenyl H H 2.60.8 7.21
10[b] N-aminophenyl benzyl H H 2.31 3.10.4
11 N-amino(3-chlorophenyl) benzyl H H 0.480.16 7.81.3
12 N-amino(3-chlorophenyl) 4-fluorobenzyl H H 1.50.3 5.71.3
13 N-amino(4-methoxybenzyl) benzyl H H 3.00.5 1.30.2
14 N-aminobenzyl benzyl H 8-OMe 0.60.06 102
[a] Measurements were carried out in triplicate, and results are expressed as the mean SD. [b] Screened as
the HCl salt.
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We next focused on purchasing and synthesizing com-
pounds related to DBeQ (see Supporting Information ta-
bles S3–S6 for a complete listing of analogues and correspond-
ing p97 inhibition values). The target analogues were prepared
via the general synthetic route in Scheme 1, which features
a modular approach where N2
and N4 can be varied independ-
ently (individual experimental
details and characterization for
all new compounds can be
found in the Experimental Sec-
tion below, or in the Supporting
Information). We first replaced
the N2 and N4 benzyl groups
with phenyl groups, resulting in
a slight decrease in potency
(Table 1, 9). Incorporation of sub-
stituents on the phenyl rings
had a more substantial negative
effect on p97 inhibition (Sup-
porting Information table S3).
Replacing only the N2 benzyl
group of DBeQ with an N2
phenyl group also resulted in
decreased potency (Table 1, 10) ;
however, in this case substitu-
tion on the N2 phenyl did not
have the serious deleterious
effect as before. In fact,
a number of halide-containing
analogues possessed improved potency in the enzymatic
ATPase assay (e.g. compound 11, Table 1, and Supporting Infor-
mation table S4). The ATPase potency gains of these analogues
were offset by a slight decrease in potency in the UbG76V–GFP
degradation assay. Nonetheless, encouraged by these initial re-
sults, we next explored the effect of substitution on the N4
benzyl group while incorporating the 3-chlorophenyl substitu-
tion of 11. Neither electron-donating- nor electron-withdraw-
ing-group-substituted analogues were able to match the po-
tency of DBeQ in the cell-based UbG76V–GFP degradation assay
(Table 1 and Supporting Information table S5). Substitution of
the N2 benzyl aromatic ring of DBeQ was also surveyed, afford-
ing several analogues possessing marginally better cell-based
potency, most notably 13 (Table 1 and Supporting Information
table S6).
In a complementary approach, we investigated the effect of
substitution on the quinazoline core (Supporting Information
table S7). The most potent compound incorporated a methoxy
group at the 8-position of the quinazoline ring (Table 1, 14)
and exhibited a threefold improvement in ATPase inhibition
counterbalanced with a fourfold erosion in the UbG76V–GFP
assay.
Based on the results from varying the substitutions on the
HTS hits 1 and DBeQ, we decided to explore more diverse moi-
eties at the N2 position. Several constrained analogues were
synthesized (for complete results, see Supporting Information
tables S8 and S9), yielding two potent p97 inhibitors 15 and
16 (Figure 3) possessing in vitro ATPase IC50 values in the sub-
micromolar range. Holding the N2 position substitution con-
stant for each of these lead compounds, we turned our atten-
tion toward optimizing the quinazoline core. Initial efforts led
to analogues with markedly different core structures possess-
ing even better ATPase potency (e.g. 17 and 18, Figure 3) ;
however, these potency gains did not translate to improve-
ments in the cell-based potency. Further modifications to the
quinazoline core ultimately afforded two probe compounds
ML241 and ML240 bearing different N2 position substitutions
on distinct quinazoline core scaffolds (Figure 3 and Supporting
Information tables S9 and S10). Although ML240 and ML241
exhibited similar potencies in the ATPase assay (IC50~0.1 mm),
ML240 was modestly more potent in the UbG76V–GFP stabiliza-
tion assay (IC50 0.9 versus 3.5 mm). Exploration into replace-
ments for the benzimidazole moiety of ML240 failed to yield
superior analogues and was not pursued further (e.g. 19 and
20, Figure 3 and Supporting Information tables S11 and S12). A
survey of ML240 analogues examining substitution on the ben-
Scheme 1. General synthetic route to DBeQ analogues. Reagents and condi-
tions: a) R2R3NH, Et3N, CH3CN, RT, 16 h; b) R
4R5NH, CH3CN, microwave irradia-
tion, 180 8C, 1 h.
Figure 3. Structures and p97 inhibitory activities for key analogues in the development of ML240 and ML241. IC50
values for inhibition of p97 ATPase activity and degradation of p97-dependent reporter UbG76V–GFP are shown.
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zimidazole moiety (Table 2) re-
vealed three compounds with
improved ATPase potency (27,
29, and 30), although no ana-
logues were found with im-
proved cell-based potency. A
survey of ML241 analogues cov-
ering substitution at the N4 po-
sition as well as modification of
the quinazoline core is summar-
ized in Table 3. Analogue 33 pos-
sessed activity approaching
ML241 and several analogues
with more radical modifications
retained most of the ML241 ac-
tivity (e.g. 17 and 41). Even the
severely truncated analogues 31
and 32 retained a portion of the
in vitro inhibition. Analogous to
the ML240 series, introduction of
a methoxy group at the C8 posi-
tion of the quinazoline core
(Table 3, 38) afforded an ana-
logue of improved potency in
the ATPase and UbG76V–GFP
assays (relative to 15, Figure 3).
A number of analogues for this
series were synthesized with the
specific aim to improve the
aqueous solubility by introduc-
ing hydrophilic groups tethered
to the phenol at the 8-position
(e.g. 33–35 and 39, Table 3).
These efforts were largely suc-
cessful, as the analogues re-
tained most if not all of the potency observed in the probe
molecule ML241.
Cell-based on-target, off-target, and antiproliferative
activities of the top 22 compounds
The top compounds that emerged from the main SAR effort
were next tested for their ability to retard degradation of the
p97-independent proteasome substrate ODD-Luc[23] (Table 4).
ODD-Luc is targeted to the proteasome via the CRL2VHL ubiqui-
tin ligase pathway. To confirm that compounds did not inter-
fere with measurement of luciferase activity, western blot anal-
ysis of ODD-Luc degradation was performed in parallel (Sup-
porting Information figure S1). Both probe compounds and
DBeQ were more than 10-fold less potent at stabilizing this
substrate. A similar trend was observed for most of the ML240/
ML241 analogues tested, with only 19 and, to a lesser extent,
17 appreciably blocking ODD-Luc degradation. The DBeQ ana-
logues were slightly less selective, most notably 14 and 52.
Compound 52 is likely to block other components within the
ubiquitin proteasome system.
Table 2. Selected SAR related to the optimization of ML240.
IC50 [mm]
[a]
Compd R1 ATPase UbG76V–GFP
ML240 H 0.110.03 0.90.1
21 5,6-dichloro 258 >20
22 5,6-dimethyl 20.4 8939
23 mixture of 5- and 6-chloro 0.70.3 317
24 mixture of 5- and 6-bromo 0.80.3 3010
25 mixture of 5- and 6-methyl 0.240.06 2.50.5
26 mixture of 5- and 6-methoxy 0.480.09 0.960.2
27 4-fluoro 0.0430.01 5.41.2
28 7-fluoro 0.50.1 5.40.8
29 4-methyl 0.0450.006 2.60.3
30 mixture of 5- and 6-fluoro 0.080.02 6.81
[a] Measurements were carried out in triplicate, and results are expressed
as the mean SD.
Table 3. Selected SAR related to the optimization of ML241.
IC50 [mm]
[a]
Compd R1 R2 ATPase UbG76V–GFP
ML241 see Figure 3 0.110.03 3.50.4
31 1.10.2 101
32 2.90.2 273
33 OCH2CH2OH benzyl 0.170.05 3.80.8
34 OCH2CH2OMe benzyl 0.60.03 6.50.7
35 OCH2CH2NEt2 benzyl 0.40.08 5.30.6
36 4-methoxyphenyl benzyl 1.10.1 91
37 n-butoxy benzyl 2.630.7 283
38 methoxy benzyl 0.20.02 3.30.4
39 OCH2CN benzyl 0.40.08 7.70.7
40 methoxy 4-fluorobenzyl 1.90.4 3.70.6
41 methoxy thiophen-2-ylmethyl 1.20.2 30.6
42 methoxy cyclohexylmethyl 7.40.9 8.21
43 methoxy 2-hyrdoxylbenzyl 4.61 60.6
[a] Measurements were carried out in triplicate, and results are expressed as the mean SD.
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We next assayed the antiproliferative activity of the com-
pounds on two colon cancer cell lines (HCT15 and SW403)
after 24 or 72 h treatment (Table 4). To our surprise, ML240 and
ML241 exhibited strikingly different antiproliferative activities.
Whereas ML240 was only fourfold more potent than ML241 at
stabilizing UbG76V–GFP, it was 24- to 70-fold more potent at
blocking cell proliferation. ML240, but not ML241, also induced
efficient cleavage of the caspase substrate, poly(ADP-ribose)
polymerase (PARP; Figure 4A), suggesting that its effects on
cell proliferation were accompanied by induction of apoptosis.
Inhibition of p97 by ML240 and ML241 is ATP competitive
To determine the mechanism by which ML240 and ML241 in-
hibited p97 ATPase, we evaluated rates of ATP hydrolysis at dif-
ferent concentrations of ATP. ML240 and ML241 inhibited p97
competitively with respect to ATP with a Ki values of 0.22 mm
(Figure 5a) and 0.35 mm (Figure 5b), respectively.
Evaluation of the effects of ML240 and ML241 on the ERAD
and autophagy pathways
Consistent with the role of p97 in the ubiquitin–proteasome
system (UPS), ML240 and ML241, like the parent compound
DBeQ, caused accumulation of ubiquitin conjugates in the nu-
clear plus membrane and cytosolic compartments at concen-
trations of 5–10 mm (Figure 4a). Interestingly, ML241 caused
stronger accumulation than ML240, even though ML240 was
more potent at stabilizing UbG76V–GFP. This, along with the cell
proliferation data, points to unexpected complexity in the
mechanism of action of these compounds. In addition to its
effect on ubiquitin conjugates, DBeQ inhibits both the ERAD
and autophagy pathways.[22] We therefore sought to evaluate
the impact of ML240 and ML241 on the ERAD reporters TCRa–
GFP (a chain of the T-cell receptor fused to GFP) and F508D
CFTR (cystic fibrosis transmembrane conductance regulator), as
well as the autophagy reporter LC3-II. TCRa–GFP overex-
pressed in non-T-cells inserts into the endoplasmic reticulum
(ER), but behaves as an unfolded protein and is degraded by
the proteasome in a p97-dependent manner.[24] ML241 had
a modest effect on TCRa–GFP, but ML240 caused more sub-
stantial accumulation of this reporter, particularly in the insolu-
ble (Ins) fraction, and to a lesser extent in the “nucleus plus
membrane” (NM) fraction (Figure 4b). Furthermore, both com-
pounds promoted accumulation of wild-type and the F508D
mutant form of CFTR (albeit less strongly than MG132), which
is normally rapidly degraded via the ERAD pathway (Fig-
ure 4c,d). Interestingly, only ML240 induced accumulation of
the lipidated LC3-II species, which is indicative of a defect in
autophagosome maturation (Figure 4c). Overall, ML240 be-
haved similarly to DBeQ in impinging on all of the p97-depen-
dent processes we tested and inducing caspase activation and
Table 4. Compilation of further characterization experiments on promising p97 inhibitor analogues.
IC50 [mm]
[a] Cytotoxicity GI50 [mm]
[a]
HCT15 SW403
Compd R1 R2 ATPase UbG76V–GFP ODD-Luc 24 h 72 h 24 h 72 h
DBeQ see Figure 1 1.6 2.3 5614 3.21.0 1.80.7 2.20.6 1.40.5
11[c] see Table 1 0.4 7.8 NM[b] 51 2.50.6 5.42 4.11.7
14[c] see Table 1 0.6 10 6.51.1 1.10.3 0.80.3 0.80.3 0.50.2
44[c] H 3-fluorophenyl 1.6 2.7 NM[b] 5.81.6 3.10.9 5.62.4 4.31.8
45[c] H 4-methylbenzyl 3 1.5 165 3.61.2 3.51.2 3.31.1 20.7
46[c] H 4-trifluoromethylbenzyl 2.6 2.5 153 3.41.1 21 3.01 1.60.7
47[c] H 3-methoxybenzyl 4.5 1.7 >20 4.41.6 3.91.5 4.72.2 30.9
48[c] H 3-fluorobenzyl 3.1 1.1 113 3.41 3.51.2 4.62 2.60.7
49[c] H 3-bromobenzyl 3.7 1.3 123 3.41.2 3.51.2 4.31.9 2.80.7
50[c] methoxy 3-chlorophenyl 0.5 5.4 184 296 194 125 115
51[c] methoxy 3-fluorophenyl 0.5 4.8 224 8.02.7 3.71.3 4.92.0 41.6
52[c] methoxy thiophen-2-ylmethyl 1.7 1.8 41 0.820.17 0.70.3 0.50.1 0.350.1
ML240 see Figure 3 0.1 0.9 287 0.760.14 0.540.19 0.50.07 0.50.1
19[d] see Figure 3 0.3 7.8 102 1.70.8 1.40.5 1.70.7 1.40.5
ML241 see Figure 3 0.1 3.5 468 535 134 337 123
15[e] see Figure 3 0.6 7 >20 243 103 215 134
17[e] see Figure 3 0.4 6.4 172 377 165 1810 9.73.7
33[e] see Table 3 0.1 3.8 >20 283 175 429 9.42.9
34[e] see Table 3 0.6 6.5 275 124 93 157 7.92.7
35[e] see Table 3 0.4 5.3 616 135 7.12.5 115 3.91
38[e] see Table 3 0.2 3.3 >20 255 123 4311 134
40[e] see Table 3 1.9 3.7 >20 274 8.92.3 216 9.42.6
[a] Measurements were carried out in triplicate, and results are expressed as the mean SD. [b] Not measured due to interference with luciferase assay.
[c] Analogue of DBeQ. [d] Analogue of ML240. [e] Analogue of ML241.
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a decrease in cell proliferation.[22] The lack of effect of ML241
on the autophagy pathway may explain why it did not cause
rapid cell death. Most importantly, these data suggest that it is
possible to develop pathway-specific inhibitors that inhibit dis-
tinct p97 functions.
ML240 induces multiple markers diagnostic of p97
inhibition
The blockade in autophagosome maturation induced by
ML240 was not an indirect consequence of apoptosis activa-
tion,[25] because LC3-II accumulated as early as 10 min after ad-
dition of drug, whereas the drug-induced PARP cleavage
shown in Figure 4a was not observed even after 40 min (Fig-
ure 4e). In parallel with the nearly immediate imposition of
a block to autophagosome maturation, we observed rapid acti-
vation of the unfolded protein response (UPR) upon addition
of ML240, as judged by accumulation of the ER stress-induced
transcription factor, activating transcription factor 4 (ATF4; Fig-
ure 4e). Together, these data indicate that inhibition of p97
profoundly disrupts protein homeostasis within minutes.
To identify other markers for p97 inhibition, we surveyed the
degradation of several UPS substrates—including IkBa, cy-
Figure 4. ML240 and ML241 impair the endoplasmic-reticulum-associated
degradation (ERAD) pathway, and only ML240 impairs the autophagy path-
way and induces apoptosis. a) SW403 cells were treated with DMSO or com-
pounds for 2 h. The indicated proteins were evaluated by immunoblotting
cytosolic (Cyto) and nuclear plus membrane (NM) fractions. b) HEK293 cells
stably expressing TCRa–GFP were used to determine the effect of ML240
and ML241 on the ERAD pathway. Cells were treated with MG132, washed,
and then incubated in the presence of cycloheximide plus compounds for
2.5 h. The indicated proteins were evaluated by immunoblotting cytosolic
(Cyto), nuclear plus membrane (NM) and insoluble (Ins) fractions. c) HEK293
cells were transfected with wild-type CFTR cDNA and treated with DMSO or
compounds for 5 h. Cytosolic fractions were immunoblotted to detect CFTR,
GAPDH, and LC3. d) HEK293 cells were transfected with F508D CFTR cDNA
and treated with DMSO or compounds for 5 h. Cytosolic fractions were im-
munoblotted to detect CFTR, a-tubulin, and p21. e) HCT116 cells were treat-
ed with ML240 (10 mm) for 0–40 min, and samples were immunoblotted to
detect the indicated proteins (ATF4: nuclear plus membrane fraction, p27
and LC3: cytosolic fraction). f) U2OS cells were transfected with negative
control siRNA (NC) or p97 siRNA (10 nm) for 72 h, and degradation of the in-
dicated proteins was determined by immunoblotting of total cell extracts
after addition of cycloheximide (CHX) for 0, 1, and 2 h. g) HT29 cells were in-
cubated with ML240 (0.4, 2, or 5 mm) for 0 to 23 h. The levels of the indicat-
ed proteins were determined by immunoblotting. (ATF4, CHOP, p27, and
p21: nuclear plus membrane fraction, and LC3: cytosolic fraction).
Figure 5. Michaelis–Menten plots for inhibition of p97 ATPase activity by
a) ML240 and b) ML241.
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clin E, p21, and p27—in cells depleted of p97 by siRNA. The
most dramatic effects were observed for p27 and p21, which
were strongly stabilized in p97-depleted cells (Figure 4 f). Con-
sistent with the effects of p97 depletion,[22] ML240 increased
the levels of ATF4, CHOP, p27, p21, and LC3-II in concentration-
and time-dependent manners (Figure 4g). The decreases in
protein levels observed upon exposure to 5 mm ML240 for
23 h were potentially caused by cell death.
ML240 induces executioner caspases 3 and 7 and triggers
cell death independently of apical caspases 8 and 9
In our prior study, 10 mm DBeQ rapidly promoted activation of
the “executioner” caspases 3 and 7 in HeLa cells, which mim-
icked p97 depletion by siRNA.[22] ML240 induced caspase activi-
ty in a dose- (Figure 6a) and time-dependent (Figure 6b,c)
manner in multiple colon cancer cell lines. By comparison,
ML240 was more effective at inducing caspase activity than
DBeQ (Figure 6b,c). Activation of caspases 3 and 7 by ML240
was specific, because it was blocked by the caspase inhibitor
Z-VAD(OMe)FMK (Figure 6d). Interestingly, although the ability
of ML240 to activate caspases 3 and 7 was not potentiated by
MG132, these two compounds had a synergistic effect on cell
proliferation (Figure 6e,f). The caspase inhibitor Z-VAD-
(OMe)FMK had a protective effect on cell proliferation, whereas
the necroptosis inhibitor Necrostatin-1 (Nec-1)[26] did not (Fig-
ure 6 f). Therefore, the rapid cell death induced by ML240 is
most likely elicited by the apoptotic pathway.
To evaluate the role of initiator caspases in activation of cas-
pases 3 and 7 by ML240, we compared caspases 3 and 7 acti-
vation in four human Jurkat cell lines: caspase-9-deficient cells
(C9/), C9/ reconstituted with caspase 9 cDNA (WT C9),
caspase-8-deficient cells (C8/), or the parental clone
(WT C8) (Figure 7). ML240 (3.3 mm) activated caspases 3 and 7
by 10-fold within 8.5 h regardless of the status of initiator cas-
pases 8 or 9 (Figure 7a). In contrast, staurosporine (STS) was
much more effective at inducing caspases 3 and 7 (Figure 7b)
and restricting cell proliferation (Figure 7c) when the intrinsic
caspase 9 apoptotic pathway was intact. Taken together, our
data suggest that ML240 does not induce caspases 3 and 7 via
the apical caspases, but more directly impinges on the execu-
tioner caspases or their immediate regulators (e.g. IAP pro-
teins). More work is required to understand how ML240 acti-
vates caspases 3 and 7, and how this relates to the inhibition
of p97.
To determine whether the antiproliferative activity of ML240
might be selective for cancer cell lines, we employed HMEC
(primary human mammary epithelial cells), PHMLEB (HMEC im-
mortalized with SV40 and hTert), and PHMLER (PHMLEB trans-
formed by H-Ras) cells.[27] Both the proteasome inhibitor borte-
zomib and the autophagy inhibitor bafilomycin blocked prolif-
eration of the normal, immortalized, and tumorigenic cell lines
with equal potency (Figure 8a,b). In contrast, DBeQ (Figure 8c)
and ML240 (Figure 8d) exhibited slightly greater potency
toward the immortalized and transformed cells.
Evaluation of ML240 and ML241 in the NCI 60-cell-line
panel
The probe molecules ML240 and ML241 were assessed for in-
hibition of cell growth in the National Cancer Institute (NCI)
60-cell-line screen. The aggregate results for all 60 cell lines are
summarized in Table 5 (see Supporting Information figures S2
and S3 for individual cell line results). The mean growth per-
cent for ML240 was negative, indicating a decrease in tumor
cell density, whereas ML241 was positive, indicating an in-
crease in tumor cell density during the 48 h assay time period,
although ML241 still displayed a slight decrease in overall
growth rate relative to control. The striking difference in anti-
proliferative activity is likely a consequence of the aforemen-
tioned findings that ML240 activates the executioner caspases
3 and 7, while ML241 does not. A notable feature of the NCI-
60 screen is that the growth inhibitory effects of ML240 cluster
in a narrow range, suggesting that specific genotypes do not
greatly influence cellular sensitivity to this compound.
Profiling of ML240 and ML241 in kinase/CNS panels and in
vitro PK evaluation
The quinazoline scaffold at the heart of ML240 and ML241 is
found in compounds that inhibit protein kinases.[28] To uncover
potential off-target effects of these compounds on protein kin-
ases, kinase profiling was performed by using an activity-based
proteomics platform (KiNativ, ActivX Biosciences, Inc. , San
Diego, CA, USA). This assay measures the ability of small mole-
cules to inhibit the covalent labeling of protein kinases in
native cell lysates by a broadly reactive ATP acyl-phosphate
probe.[29] As a positive control, we carried out a parallel analy-
sis with the protein kinase inhibitor pyrazolopyrimidine (ACJI-
47).[30] The full results from these analyses are presented in
Supporting Information table S14. Remarkably, ML241 (20 mm)
did not appreciably inhibit labeling of any of the ~170 kinases
that were evaluated, whereas ML240 inhibited labeling of only
three protein kinase domains by >50% when tested at 20 mm :
PIP5K3 (a member of the phosphoinositide-3 kinase family),
JAK1 JH2 (N-terminal pseudokinase domain of JAK1), and DNA-
dependent protein kinase (DNAPK). In contrast, pyrazolopyrimi-
Table 5. Aggregate NCI 60-cell-line screening results.
Compd Mean GP [%][a] Lowest GP [%][b] Highest GP [%][c]
ML240 84.515.5 100.0 (OVCAR-4) 43.8 (HS 578T)
ML241 92.822.8 111.9 (HS 578T) 69.9 (MDA-MB-231/ATCC)
[a] Growth percent (GP) for individual cell lines calculated as follows: for
negative growth, GP=100 (ODtestODT=0)/ODT=0 ; for positive growth,
GP=100 (ODtestODT=0)/(ODcontrolODT=0), for which GP is growth per-
cent, ODtest is the optical density of the test culture after 48 h, ODT=0 is
the optical density of the test culture before addition of compound, and
ODcontrol is the optical density of the control culture after 48 h; values rep-
resent the mean of 60 NCI cell lines SD. [b] Growth percent of the most
inhibited individual cancer cell line. [c] Growth percent of the least inhib-
ited individual cancer cell line.
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dine exhibited >50% inhibition of 56 protein kinases when
tested at the same concentration. We therefore concluded that
both ML240 and ML241 are quite specific, showing little activi-
ty against the targets assessed here.
In an effort to gauge the potential for off-target effects of
these compounds, the binding affinity (Ki values) of DBeQ,
ML240, and ML241 were determined for a panel of 43 CNS-rel-
evant receptors and targets (Figure 9). While DBeQ was found
to possess significant binding affinity (Ki values of <10 mm) for
23 targets (with 15 targets found to be <1 mm), ML240 was
found to only have significant binding affinity for the 5HT5a
receptor (Ki=2.5 mm), and ML241 was found to possess signifi-
cant binding affinity for eight targets (with only three targets
<1 mm). The substantial improvement in selectivity for ML241
and the remarkably clean profile for ML240 bode well for their
utility as in vivo probes and the therapeutic potential of this
chemotype in general.
Finally, ML240 and ML241 were subjected to a panel of stan-
dard in vitro pharmacokinetic (PK) assays (Table 6). Encourag-
ingly, both compounds possessed excellent plasma stability
Figure 6. ML240 induces activation of caspases 3 and 7 and apoptosis. a) MIN and CIN colon cancer lines were treated with ML240 (1.1, 3.3, 10, or 20 mm) for
7 h prior to determination of caspase 3 and 7 activities in cell extract. Caspase 3 and 7 activities were normalized to the intensity of DMSO treated cells.
b) HCT116 cells were incubated with 10 mm DBeQ, ML240, STS (staurosporine) or 20 mm bortezomib for 3, 7, 10, or 20 h prior to determination of caspase 3
and 7 activities in the cell extract. c) Same as panel b, except HT29 cells were used. d) Colon cancer cell lines were treated with ML240 (10 mm) plus either
DMSO, CHX (50 mm), MG132 (10 mm), Z-VAD (25 mm), or Nec-1 (20 mm) for 7 h prior to determination of caspase 3 and 7 activities in the cell extract. e) Same
as panel d, except cellular viability was determined using CellTiter-Glo. f) Viability of HCT15 cells was determined using CellTiter-Glo after co-treatment with
various concentrations of ML240 (0–20 mm) plus either DMSO, CHX (50 mm), MG132 (10 mm), Z-VAD (25 mm), or Nec-1 (20 mm) for 7 h.
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and acceptable human microsomal stability, with ML240 less
susceptible to degradation than ML241. ML241 was also non-
toxic toward Fa2N-4 immortalized human hepatocytes, al-
though ML240 was less benign. In the parallel artificial mem-
brane permeability assay (PAMPA), ML241 was again found to
perform better than ML240, although this could be attributed
to the adjusted assay conditions (addition of 20% acetonitrile).
The aqueous solubility of ML241 was decent at low pH
(pH 5.0) and poor at other pH values tested, whereas ML240
possessed poor solubility at all tested pH levels. Finally, both
compounds were highly bound in the presence of plasma pro-
tein. The poor solubility and high plasma protein binding activ-
ity of these probes will need to be taken into consideration by
researchers who use these compounds to investigate p97
function. To overcome these issues, we suggest that assays
using these compounds should be carried out at a final con-
Figure 7. Cell death induced by ML240 is independent of caspases 8 and 9.
Jurkat cells deficient in caspase 9 (C9/), C9/ reconstituted with cas-
pase 9 cDNA (WT C9), deficient in caspase 8 (C8/), or the parental clone
(WT C8) were exposed to the indicated concentrations of a) ML240 or
b) staurosporine (STS) for 8.5 h prior to determination of caspase 3 and 7 ac-
tivities in the cell extract, and caspase 3 and 7 activities were normalized to
the intensity of DMSO treated cells. c) Same as panel b, except incubation
was for 24 h prior to determining cellular viability.
Figure 8. ML240 and DBeQ exhibit a modest therapeutic index. HMEC (pri-
mary human mammary epithelial cells), PHMLEB (sv40 and hTert immortal-
ized), and PHMLER (H-Ras tumorigenic) cells were incubated with the indi-
cated concentrations of a) bortezomib, b) bafilomycin (Baf), c) DBeQ, or
d) ML240 for 24 h. Cellular viability was determined using CellTiter-Glo. Cel-
lular viability was normalized to DMSO treated cells.
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centration of 1% DMSO following 100-fold dilution from
a DMSO stock. Cell-based experiments should be carried out in
2.5–5% FBS.
Conclusions
We developed two probes, ML240 and ML241, for the further
study of p97 functions. The probes arose from a focused SAR
campaign based on the 2,4-disubstituted quinazoline chemo-
type mined from the NIH compound collection (AID 1794,
http://pubchem.ncbi.nlm.nih.gov/).[22] The wide range of
known cellular functions involving the p97 enzyme underscore
the importance of developing selective p97 inhibitors, which
would be highly useful to better understand the precise func-
tion of p97 in normal and aberrant physiological systems. Both
probes are useful inhibitors of the p97 enzyme and share
many similar structural elements; however, ML240, like the
parent compound DBeQ,[22] is capable of inhibiting the auto-
phagic degradation pathway and activating caspases 3 and 7
and inducing rapid cell death, whereas ML241 is not. The dif-
ferential ability of these compounds to induce apoptosis sug-
gests either that rapid cell death was due to inhibition of the
autophagic function of p97, or required simultaneous blockade
of p97 function in both the autophagy and ubiquitin-protea-
some pathways. Alternatively, apoptosis may be triggered by
inhibition of a novel p97 function that has not been evaluated
in our studies. Regardless of the
precise explanation for the dif-
ferential activity of these com-
pounds, the more selective be-
havior of ML241 suggests that
developing pathway-specific p97
inhibitors may prove to be a val-
uable approach to study the role
of p97 in regulating a variety of
cellular pathways.[31] Pathway-se-
lective p97 inhibitors with differ-
ential effects on apoptosis in-
duction may enable the devel-
opment of therapies that target
p97 activity in diverse clinical
settings, including IBMPFD (in-
clusion body myopathy associat-
ed with Paget disease of bone
and frontotemporal demen-
tia),[10,11] retinitis pigmentosa,[32] and cancer.[33] Understanding
the basis of the divergent activities of ML240 and ML241 as
well as potentially exploiting such effects toward the develop-
ment of novel therapeutics are the aim of ongoing studies.
Experimental Section
Biology
ATPase assay : The detailed methodology was described previous-
ly.[22] To avoid compounds forming colloids that cause nonspecific
enzyme inhibition,[34] inhibition of p97 was carried out in the assay
buffer (50 mm Tris pH 7.4, 20 mm MgCl2, 1 mm EDTA, 0.5 mm TCEP)
containing 0.01% Triton X-100. ATPase activity was determined by
the addition of biomol green reagent (Enzo Life Sciences).
Reporter degradation assay : The dual reporter stable HeLa cell line
that expresses the UFD reporter UbG76V–GFP[35] and the oxygen-de-
pendent degradation domain of HIF1a fused to luciferase (ODD-
Luc)[36] was described previously.[23] Cellular caspase activity, cellular
viability, and western blot analysis were described previously.[22]
Cell culture : Colon cancer cell lines were maintained in DMEM sup-
plemented with 5% FBS and antibiotics (Invitrogen). The human
Jurkat T-cell line was maintained in RPMI 1640 medium supple-
mented with 5% FBS and antibiotics (Invitrogen). PHMLEB,
PHMLER, and primary HMEC (Lonza) were propagated in MEGM
mammary epithelial cell medium with mammary epithelial growth
Figure 9. Binding affinity (Ki [nm]) for DBeQ, ML240, and ML241 toward 43 CNS-relevant targets.
Table 6. Summary of in vitro pharmacokinetic properties for ML240 and ML241.
Compd Aqueous solubility
[mgmL1][a]
PAMPA Pe
[106 cms1][b]
PPB [%][c] PS [%][d] HMS [%][e] LC50 [mm]
[f]
human mouse
ML240 0.35 (5.0)/0.33 (6.2)/0.27 (7.4) 357 (5.0)/628 (6.2)/<60.3 (7.4) 99.53/99.71 99.73/99.63 100/100 54.28/0.63 8.5
ML241 28 (5.0)/0.13 (6.2)/0.20 (7.4) 1164 (5.0)[g]/2504 (6.2)[g]/2278 (7.4)[g] 99.97/99.95 99.95/99.91 100/100 18.97/2.57 >50
[a] In aqueous buffer, pH 5.0/6.2/7.4. [b] In aqueous buffer, donor compartment pH 5.0/6.2/7.4 ; acceptor compartment pH 7.4. [c] Plasma protein bound,
1 mm/10 mm. [d] Plasma stability, percent remaining at 3 h; human/mouse. [e] Hepatic microsome stability, percent remaining at 1 h; human/mouse. [f] Hep-
atic toxicity toward Fa2N-4 immortalized human hepatocytes. [g] In the presence of 20% CH3CN.
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supplement (Invitrogen). Kinase profiling was described previous-
ly[22] except that PC3 cell lysate was used.
Chemistry
General : All reagents were used as received. CH3CN, CH2Cl2, tolu-
ene and THF were purified using the Innovative Technology Pure-
Solv solvent purification system. 1H and 13C spectra were recorded
on a Bruker Avance 400 or 500 MHz spectrometer. Chemical shifts
(d) are reported in parts per million and were referenced to residu-
al proton solvent signals. Flash column chromatography separa-
tions were performed using the Teledyne Isco CombiFlash Rf using
RediSep Rf silica gel columns. TLC was performed on Analtech Uni-
plate silica gel GHLF (gypsum inorganic hard layer with fluores-
cence) plates. TLC plates were developed using iodine vapor. Auto-
mated preparative RP HPLC purification was performed using an
Agilent 1200 mass-directed fractionation system (prep pump
G1361 with gradient extension, make-up pump G1311A, pH modifi-
cation pump G1311A, HTS PAL autosampler, UV-DAD detection
G1315D, fraction collector G1364B, and Agilent 6120 quadrupole
spectrometer G6120A). The preparative chromatography condi-
tions included a Waters X-Bridge C18 column (19150 mm, 5 mm,
with 1910 mm guard column), elution with a H2O and CH3CN
gradient, which increases to 20% CH3CN content over 4 min at
a flow rate of 20 mLmin1 (modified to pH 9.8 through the addi-
tion of NH4OH by auxiliary pump), and sample dilution in DMSO.
The preparative gradient, triggering thresholds, and UV wave-
length were selected according to the analytical RP HPLC analysis
of each crude sample. The analytical method used an Agilent 1200
RRLC system with UV detection (Agilent 1200 DAD SL) and mass
detection (Agilent 6224 TOF). The analytical method conditions in-
cluded a Waters Aquity BEH C18 column (2.150 mm, 1.7 mm) and
elution with a linear gradient of 5% CH3CN in pH 9.8 buffered
aqueous ammonium formate to 100% CH3CN at a flow rate of
0.4 mLmin1. Compound purity was measured on the basis of
peak integration (area under the curve) from UV/Vis absorbance
(l 214 nm), and compound identity was determined on the basis
of mass analysis. All compounds used for biological studies have
purity >95% with the following exceptions: 18 (81.2%), 20
(83.1%), and 35 (68.2%). DBeQ was synthesized as previously de-
scribed,[22] and compounds 1–8, 10, and 11 were purchased from
commercial vendors.
General procedure A : Representative protocol for the synthesis of
quinazoline analogues, synthesis of 16.
N-Benzyl-2-chloroquinazolin-4-amine : 2,4-dichloroquinazoline
(2.4 g, 12.3 mmol) was suspended in THF (20 mL). Et3N (2.1 mL,
14.7 mmol) was added, followed by the addition of benzylamine
(1.4 mL, 12.9 mmol). The mixture was stirred at room temperature
for 16 h. The mixture was diluted with EtOAc, filtered, and the fil-
trate was concentrated. The residue was purified by silica gel chro-
matography to give the product as a white solid (1.6 g, 47%): Rf=
0.5 (EtOAc/hexanes, 1:3) ; 1H NMR (400 MHz, CDCl3): d=7.87–7.73
(m, 2H), 7.68 (d, J=8.2 Hz, 1H), 7.54–7.32 (m, 6H), 6.10 (s, 1H),
4.90 ppm (d, J=5.3 Hz, 2H).
2-(2-Amino-1H-benzo[d]imidazol-1-yl)-N-benzylquinazolin-4-
amine (16): A suspension of N-benzyl-2-chloroquinazolin-4-amine
(0.015 g, 0.056 mmol) and 1H-benzo[d]imidazol-2-amine (0.015 g,
0.111 mmol) in CH3CN (1 mL) was heated in a synthesis microwave
at 180 8C for 1 h. The solvent was removed in vacuo and the crude
sample was purified via reversed-phase preparative HPLC to give
16 as a white solid (6.8 mg, 33%): 1H NMR (400 MHz, [D6]DMSO):
d=9.42 (t, J=5.8 Hz, 1H), 8.41 (d, J=8.1 Hz, 1H), 8.12 (d, J=
7.5 Hz, 1H), 7.94–7.79 (m, 4H), 7.54–7.50 (m, 1H), 7.45 (d, J=
7.1 Hz, 2H), 7.37 (t, J=7.6 Hz, 2H), 7.27 (t, J=7.3 Hz, 1H), 7.15 (d,
J=7.1 Hz, 1H), 7.03 (td, J=1.2, 7.6 Hz, 1H), 6.88–6.76 (m, 1H),
4.91 ppm (d, J=5.8 Hz, 2H); 13C NMR (126 MHz, [D6]DMSO): d=
160.7, 154.5, 154.1, 148.9, 142.8, 138.4, 133.7, 131.7, 128.5, 127.0,
126.6, 125.1, 123.0, 122.5, 118.7, 114.8, 112.5, 44.4 ppm; HRMS-ESI :
m/z [M+H]+ calcd for C22H19N6: 367.1671, found: 367.1685; HPLC
purity: 96.1%.
General procedure B : Representative protocol for the synthesis of
8-O-alkylation analogues, synthesis of 39.
2-(2H-Benzo[b][1,4]oxazin-4(3H)-yl)-4-(benzylamino)quinazolin-8-
ol : To a solution of 2-(2H-benzo[b][1,4]oxazin-4(3H)-yl)-N-benzyl-8-
methoxyquinazolin-4-amine (2.6 mg, 6.5 mmol) in CH2Cl2 (0.5 mL)
at 0 8C, was added BBr3 (39 mL, 39 mmol, 1m in CH2Cl2). The mix-
ture was stirred at room temperature for 16 h. The reaction was
quenched with slow addition of H2O. After extraction with CH2Cl2,
the organic layer was dried over MgSO4, evaporated under vacuum
to give the product as a brown oil (19.0 mg, 62%): 1H NMR
(400 MHz, CDCl3): d=7.88 (s, 1H), 7.30 (d, J=4.6 Hz, 4H), 7.28–7.21
(m, 1H), 7.09–7.06 (m, 2H), 7.02–6.88 (m, 2H), 6.86 (d, J=6.5 Hz,
1H), 6.79–6.74 (m, 1H), 4.76 (d, J=5.4 Hz, 2H), 4.23 ppm (s, 4H);
HRMS-ESI : m/z [M+H]+ calcd for C23H21N4O2: 385.1665, found:
385.1657.
2-((2-(2H-Benzo[b][1,4]oxazin-4(3H)-yl)-4-(benzylamino)quinazo-
lin-8-yl)oxy)acetonitrile (39): To a suspension of 2-(2H-benzo[b]-
[1,4]oxazin-4(3H)-yl)-4-(benzylamino)quinazolin-8-ol (0.012 g,
0.031 mmol) and K2CO3 (0.013 g, 0.094 mmol) in DMF (1 mL), was
added 2-chloroacetonitrile (3.0 mL, 0.047 mmol). The mixture was
stirred at 80 8C for 16 h. The reaction was monitored by LC–MS.
The reaction was complete after 16 h. DMF was removed under
vacuum. The product was purified by silica gel chromatography to
afford a brown solid (3.3 mg, 25%): Rf=0.6 (EtOAc/hexanes, 1:2) ;
1H NMR (400 MHz, CDCl3): d=7.99 (dd, J=1.5, 8.3 Hz, 1H), 7.34–
7.29 (m, 3H), 7.29–7.22 (m, 4H), 7.07–7.01 (m, 1H), 6.93–6.81 (m,
2H), 6.79–6.71 (m, 1H), 5.84 (s, 1H), 5.11 (s, 2H), 4.73 (d, J=5.4 Hz,
2H), 4.31–4.25 (m, 2H), 4.22 ppm (dd, J=3.1, 5.0 Hz, 2H); 13C NMR
(126 MHz, CDCl3): d=159.8, 156.1, 150.2, 146.5, 144.6, 138.1, 128.9,
127.7, 124.9, 123.9, 121.6, 121.1, 119.4, 116.9, 116.8, 115.8, 112.6,
66.1, 56.5, 45.5, 42.2 ppm; HRMS-ESI: m/z [M+H]+ calcd for
C25H22N5O2: 424.1773, found: 424.1783; HPLC purity: 96.0%.
N2,N4-Diphenylquinazoline-2,4-diamine (9): 2-Chloro-N-phenylqui-
nazolin-4-amine and aniline were reacted according to general pro-
cedure A to give 9 as a white solid (11.8 mg, 97%): 1H NMR
(400 MHz, CDCl3): d=7.79–7.71 (m, 6H), 7.71–7.65 (m, 2H), 7.48–
7.42 (m, 2H), 7.40 (br s, 1H), 7.38–7.29 (m, 3H), 7.26–7.20 (m, 1H),
7.17 (br s, 1H), 7.09–7.00 ppm (m, 1H); 13C NMR (101 MHz, CDCl3):
d=158.2, 156.5, 152.0, 140.0, 138.3, 133.2, 129.0, 128.8, 126.8,
124.5, 122.7, 122.1, 122.1, 120.4, 119.5, 111.6 ppm; HRMS-ESI : m/z
[M+H]+ calcd for C20H17N4: 313.1453, found: 313.1451; HPLC
purity: 98.8%.
N2-(3-Chlorophenyl)-N4-(4-fluorobenzyl)quinazoline-2,4-diamine
(12): 2-Chloro-N-(4-fluorobenzyl)quinazolin-4-amine and 3-chloroa-
niline were reacted according to general procedure A to give 12 as
a white solid (13.0 mg, 99%): 1H NMR (400 MHz, CDCl3): d=8.00 (t,
J=2.0 Hz, 1H), 7.65–7.57 (m, 2H), 7.54 (d, J=8.2 Hz, 1H), 7.44–7.38
(m, 1H), 7.35 (dd, J=5.3, 8.7 Hz, 2H), 7.22–7.14 (m, 2H), 7.09 (br s,
1H), 7.06–6.99 (m, 2H), 6.93 (ddd, J=0.9, 2.0, 7.9 Hz, 1H), 5.89 (br s,
1H), 4.80 ppm (d, J=5.2 Hz, 2H); 13C NMR (101 MHz, CDCl3): d=
163.6, 161.1, 160.1, 156.4, 151.3, 141.6, 134.4, 133.93, 133.90, 133.1,
130.0, 129.54, 129.46, 126.6, 122.7, 121.6, 120.7, 118.9, 116.9, 115.8,
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115.6, 111.5, 44.6 ppm; HRMS-ESI: m/z [M+H]+ calcd for
C21H17ClFN4: 379.1126, found: 379.1123; HPLC purity: 100%.
N4-Benzyl-N2-(4-methoxybenzyl)quinazoline-2,4-diamine (13): 2-
Chloro-N-benzylquinazolin-4-amine and 4-methoxybenzyl amine
were reacted according to general procedure A to give 13 as
a white solid (22.0 mg, 80%): 1H NMR (400 MHz, [D6]DMSO): d=
8.44 (s, 1H), 8.03 (d, J=7.3 Hz, 1H), 7.55–7.43 (m, 1H), 7.43–7.11
(m, 8H), 7.04 (t, J=7.1 Hz, 2H), 6.82 (br s, 2H), 4.74 (d, J=4.7 Hz,
2H), 4.43 (br s, 2H), 3.70 ppm (s, 3H); 13C NMR (101 MHz,
[D6]DMSO): d=159.9, 159.8, 159.3, 157.8, 139.9, 133.2, 132.2, 129.2,
128.5, 128.2, 127.3, 126.6, 122.7, 119.9, 113.5, 113.4, 54.9, 43.4,
43.3 ppm; HRMS-ESI : m/z [M+H]+ calcd for C23H23N4O: 371.1872,
found: 371.1868; HPLC purity: 96.8%.
N2,N4-Dibenzyl-8-methoxyquinazoline-2,4-diamine (14): To a sus-
pension of 2,4-dichloro-8-methoxyquinazoline (50.0 mg,
0.22 mmol) in CH3CN (2 mL) was added benzylamine (0.12 mL,
1.1 mmol, 5 equiv). The mixture was heated at 180 8C for 1 h under
microwave irradiation. The solvent was removed under vacuum,
the residue suspended in EtOAc, washed with saturated NaHCO3,
and the layers were separated. The organic layer was dried over
MgSO4 and concentrated under vacuum. The residue was purified
by silica gel chromatography to give the product as a white solid
(14.9 mg, 18%): Rf=0.5 (EtOAc);
1H NMR (400 MHz, CDCl3): d=
7.44–7.18 (m, 11H), 7.11 (dd, J=1.6, 7.9 Hz, 1H), 7.07–6.93 (m, 2H),
5.86 (br s, 1H), 5.49 (br s, 1H), 4.78 (d, J=5.7 Hz, 2H), 4.75 (d, J=
5.7 Hz, 2H), 3.99 ppm (s, 3H); 13C NMR (101 MHz, CDCl3): d=160.1,
159.3, 153.2, 144.2, 140.2, 138.7, 128.7, 128.4, 128.0, 127.5, 126.8,
120.4, 112.5, 111.2, 110.9, 55.9, 45.7, 45.2 ppm; HRMS-ESI: m/z [M+
H]+ calcd for C23H23N4O: 371.1872, found: 371.1871; HPLC purity:
98.9%.
2-(2H-Benzo[b][1,4]oxazin-4(3H)-yl)-N-benzylquinazolin-4-amine
(15): 2-Chloro-N-benzylquinazolin-4-amine and 3,4-dihydro-2H-
benzo[b][1,4]oxazine were reacted according to general procedur-
e A to give 15 as a light-yellow oil (27.0 mg, 99%): 1H NMR
(400 MHz, CDCl3): d=8.12 (d, J=8.3 Hz, 1H), 7.68–7.61 (m, 2H),
7.58 (d, J=8.2 Hz, 1H), 7.45–7.30 (m, 5H), 7.25–7.12 (m, 1H), 7.03–
6.89 (m, 2H), 6.88–6.77 (m, 1H), 5.94 (s, 1H), 4.84 (d, J=5.5 Hz,
2H), 4.39 (dd, J=3.1, 5.1 Hz, 2H), 4.34 ppm (dd, J=3.1, 5.0 Hz, 2H);
13C NMR (101 MHz, CDCl3): d=159.8, 156.7, 151.7, 146.3, 138.5,
132.8, 128.8, 128.1, 127.7, 127.6, 126.8, 124.7, 123.4, 122.3, 120.7,
119.4, 116.7, 111.3, 66.2, 45.3, 42.2 ppm; HRMS-ESI : m/z [M+H]+
calcd for C23H21N4O: 369.1715, found: 369.1716; HPLC purity:
99.0%.
2-(2H-Benzo[b][1,4]oxazin-4(3H)-yl)-N-benzylthieno[3,2-d]pyrimi-
din-4-amine (17): N-Benzyl-2-chlorothieno[3,2-d]pyrimidin-4-amine
and 3,4-dihydro-2H-benzo[b][1,4]oxazine were reacted according to
general procedure A to give 17 as a white solid (8.2 mg, 41%):
1H NMR (500 MHz, [D6]DMSO): d=8.39 (t, J=5.9 Hz, 1H), 8.01 (d,
J=5.3 Hz, 1H), 7.86 (dd, J=1.5, 8.3 Hz, 1H), 7.36–7.29 (m, 4H),
7.28–7.21 (m, 1H), 7.19 (d, J=5.3 Hz, 1H), 6.90–6.84 (m, 1H), 6.82
(dd, J=1.7, 8.1 Hz, 1H), 6.68 (ddd, J=1.7, 7.1, 8.6 Hz, 1H), 4.66 (d,
J=5.9 Hz, 2H), 4.23–4.16 (m, 2H), 4.15–4.13 ppm (m, 2H); 13C NMR
(126 MHz, DMSO): d=160.9, 157.7, 156.7, 145.6, 139.7, 133.0, 128.3,
128.2, 127.0, 126.6, 124.3, 123.7, 122.7, 119.1, 116.2, 107.6, 65.3,
43.4, 42.1 ppm; HRMS-ESI: m/z [M+H]+ calcd for C21H19N4OS:
375.1280, found: 375.1284; HPLC purity: 95.3%.
2-(2-Amino-1H-benzo[d]imidazol-1-yl)-N-benzyl-5,6,7,8-tetrahy-
droquinazolin-4-amine (18): N-Benzyl-2-chloro-5,6,7,8-tetrahydro-
quinazolin-4-amine and 1H-benzo[d]imidazol-2-amine were reacted
according to general procedure A to give 18 as a white solid
(1.8 mg, 12%): 1H NMR (400 MHz, [D6]DMSO): d=7.92 (d, J=7.4 Hz,
1H), 7.84 (s, 1H), 7.65 (s, 2H), 7.40–7.29 (m, 4H), 7.23 (s, 1H), 7.11
(d, J=7.1 Hz, 1H), 6.99 (t, J=7.0 Hz, 1H), 6.79–6.72 (m, 1H), 4.71
(d, J=6.0 Hz, 2H), 2.70 (br s, 2H), 2.49 (br s, 2H), 1.83 ppm (br s,
4H); 13C NMR (126 MHz, DMSO): d=161.0, 160.8, 154.3, 154.1,
142.8, 139.3, 131.6, 128.3, 126.7, 126.4, 122.2, 118.6, 114.6, 114.3,
108.6, 44.1, 31.3, 21.9, 21.7, 21.6 ppm; HRMS-ESI: m/z [M+H]+
calcd for C22H23N6: 371.1984, found: 371.1989; HPLC purity: 81.2%.
2-(2H-Benzo[b][1,4]oxazin-4(3H)-yl)-N-benzyl-5,6,7,8-tetrahydro-
quinazolin-4-amine (ML241): N-Benzyl-2-chloro-5,6,7,8-tetrahydro-
quinazolin-4-amine and 3,4-dihydro-2H-benzo[b][1,4]oxazine were
reacted according to general procedure A to give ML241 as
a white solid (9.0 mg, 66%): 1H NMR (400 MHz, CDCl3): d=8.09–
8.01 (m, 1H), 7.42–7.30 (m, 5H), 6.92–6.86 (m, 2H), 6.80–6.73 (m,
1H), 4.79 (s, 1H), 4.69 (d, J=5.6 Hz, 2H), 4.28 (dd, J=3.1, 5.0 Hz,
2H), 4.23 (dd, J=3.1, 5.0 Hz, 2H), 2.67 (t, J=5.7 Hz, 2H), 2.32 (t, J=
5.7 Hz, 2H), 1.93–1.77 ppm (m, 4H); 13C NMR (101 MHz, CDCl3): d=
162.5, 160.7, 157.3, 145.9, 139.5, 128.6, 128.5, 127.5, 127.3, 123.9,
122.6, 119.5, 116.6, 103.8, 65.9, 45.0, 42.2, 32.2, 22.6, 22.5,
21.9 ppm; HRMS-ESI : m/z [M+H]+ calcd for C23H25N4O: 373.2028,
found: 373.2030; HPLC purity: 98.3%.
2-(2-Amino-1H-benzo[d]imidazol-1-yl)-N-benzyl-8-methoxyquina-
zolin-4-amine (ML240): N-Benzyl-2-chloro-8-methoxyquinazolin-4-
amine and 1H-benzo[d]imidazol-2-amine were reacted according
to general procedure A to give ML240 as a light-yellow oil
(14.6 mg, 55%): 1H NMR (400 MHz, [D6]DMSO): d=9.33 (t, J=
5.9 Hz, 1H), 8.31–8.05 (m, 3H), 7.93 (d, J=7.5 Hz, 1H), 7.50–7.39
(m, 3H), 7.39–7.30 (m, 3H), 7.25 (t, J=7.3 Hz, 1H), 7.15 (d, J=
7.1 Hz, 1H), 7.03 (td, J=1.2, 7.6 Hz, 1H), 6.87–6.76 (m, 1H), 4.92 (d,
J=5.8 Hz, 2H), 3.98 ppm (s, 3H); 13C NMR (101 MHz, [D6]DMSO):
d=160.8, 154.7, 153.5, 153.4, 142.8, 140.0, 138.5, 131.5, 128.5,
126.9, 126.6, 124.9, 122.5, 118.7, 114.8, 114.6, 114.1, 113.0, 112.7,
56.1, 44.5 ppm; HRMS-ESI: m/z [M+H]+ calcd for C23H21N6O:
397.1777, found: 397.1776; HPLC purity: 100%.
N4-Benzyl-8-methoxy-N2-(1-methyl-1H-benzo[d]imidazol-2-yl)qui-
nazoline-2,4-diamine (19): To a suspension of N-benzyl-2-chloro-8-
methoxyquinazolin-4-amine (15.0 mg, 50 mmol) in CH3CN (1 mL)
was added 1-methyl-1H-benzo[d]imidazol-2-amine (14.7 mg,
0.1 mmol, 2 equiv). The mixture was heated at 180 8C for 10 h
under microwave irradiation. The solvent was removed under
vacuum, the residue was suspended in EtOAc, washed with satu-
rated NaHCO3, and the layers were separated. The organic layer
was dried over MgSO4 and concentrated under vacuum. The resi-
due was purified by reversed-phase preparative HPLC to give 19 as
a white solid (3.9 mg, 19%): 1H NMR (500 MHz, [D6]DMSO): d=9.36
(s, 1H), 8.28 (s, 1H), 8.24 (d, J=8.0 Hz, 1H), 7.93 (d, J=7.9 Hz, 1H),
7.51 (s, 1H), 7.50–7.39 (m, 2H), 7.35 (td, J=2.7, 9.5 Hz, 3H), 7.25 (t,
J=7.3 Hz, 1H), 7.16 (d, J=5.4 Hz, 2H), 6.93 (s, 1H), 4.88 (d, J=
5.7 Hz, 2H), 3.99 (s, 3H), 3.42 ppm (s, 3H); HRMS-ESI: m/z [M+H]+
calcd for C24H23N6O: 411.1933, found: 411.1937; HPLC purity:
96.9%.
N-Benzyl-2-(3,4-dihydroisoquinolin-2(1H)-yl)quinazolin-4-amine
(20): 2-Chloro-N-benzylquinazolin-4-amine and 1,2,3,4-tetrahydroi-
soquinoline were reacted according to general procedure A to give
20 as a white solid (8.0 mg, 59%): 1H NMR (400 MHz, CDCl3): d=
7.45 (d, J=3.6 Hz, 2H), 7.41 (d, J=8.2 Hz, 1H), 7.35 (d, J=7.3 Hz,
2H), 7.33–7.21 (m, 3H), 7.16–7.03 (m, 4H), 7.03–6.89 (m, 1H), 5.73
(br s, 1H), 4.95 (s, 2H), 4.78 (d, J=5.4 Hz, 2H), 4.07 (t, J=5.9 Hz,
2H), 2.84 ppm (t, J=5.9 Hz, 2H); 13C NMR (101 MHz, CDCl3): d=
159.6, 139.0, 135.5, 134.9, 132.6, 128.7, 128.6, 127.9, 127.5, 126.6,
126.03, 125.95, 120.9, 120.7, 110.3, 46.4, 45.3, 41.5, 29.2 ppm;
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HRMS-ESI : m/z [M+H]+ calcd for C24H23N4: 367.1923, found:
367.1921; HPLC purity: 83.1%.
2-(2-Amino-5,6-dichloro-1H-benzo[d]imidazol-1-yl)-N-benzyl-8-
methoxyquinazolin-4-amine (21): N-Benzyl-2-chloro-8-methoxy-
quinazolin-4-amine and 5,6-dichloro-1H-benzo[d]imidazol-2-amine
were reacted according to general procedure A to give 21 as
a white solid (7.0 mg, 30%): 1H NMR (500 MHz, [D6]DMSO): d=9.42
(s, 1H), 8.55 (s, 1H), 8.53–8.34 (m, 2H), 7.93 (d, J=7.7 Hz, 1H),
7.52–7.41 (m, 3H), 7.38 (d, J=7.5 Hz, 1H), 7.33 (dd, J=5.8, 9.4 Hz,
3H), 7.25 (d, J=7.4 Hz, 1H), 4.90 (d, J=5.8 Hz, 2H), 3.98 ppm (s,
3H); 13C NMR (126 MHz, [D6]DMSO): d=160.7, 156.3, 153.5, 152.8,
143.2, 139.7, 138.0, 131.1, 128.5, 127.0, 126.6, 125.3, 124.7, 120.0,
115.9, 115.3, 114.1, 113.1, 112.9, 56.1, 44.5 ppm; HRMS-ESI : m/z
[M+H]+ calcd for C23H19Cl2N6O: 424.1773, found: 465.1028; HPLC
purity: 95.6%.
2-(2-Amino-5,6-dimethyl-1H-benzo[d]imidazol-1-yl)-N-benzyl-8-
methoxyquinazolin-4-amine (22): N-Benzyl-2-chloro-8-methoxy-
quinazolin-4-amine and 5,6-dimethyl-1H-benzo[d]imidazol-2-amine
were reacted according to general procedure A to give 22 as
a white solid (13.0 mg, 61%): 1H NMR (400 MHz, [D6]DMSO): d=
9.27 (t, J=6.0 Hz, 1H), 8.09 (s, 2H), 8.07 (s, 1H), 7.90 (d, J=7.5 Hz,
1H), 7.47–7.39 (m, 3H), 7.39–7.30 (m, 3H), 7.25 (t, J=7.3 Hz, 1H),
6.94 (s, 1H), 4.98 (d, J=5.9 Hz, 2H), 3.98 (s, 3H), 2.19 (s, 3H),
2.04 ppm (s, 3H); 13C NMR (101 MHz, [D6]DMSO): d=160.9, 154.2,
153.5, 140.9, 140.2, 138.5, 130.0, 129.7, 128.5, 126.9, 126.5, 126.2,
124.7, 115.7, 115.5, 114.1, 112.8, 112.7, 56.1, 44.4, 19.7 ppm; HRMS-
ESI : m/z [M+H]+ calcd for C25H25N6O: 425.2090, found: 425.2090;
HPLC purity: 94.4%.
2-(2-Amino-5-chloro-1H-benzo[d]imidazol-1-yl)-N-benzyl-8-me-
thoxyquinazolin-4-amine and 2-(2-Amino-6-chloro-1H-benzo[d]i-
midazol-1-yl)-N-benzyl-8-methoxyquinazolin-4-amine (~1:0.93)
(23): N-Benzyl-2-chloro-8-methoxyquinazolin-4-amine and 5-chloro-
1H-benzo[d]imidazol-2-amine were reacted according to general
procedure A to give 23, a white solid, as a mixture of regioisomers
(10.2 mg, 47%): 1H NMR (400 MHz, [D6]DMSO): d=9.39 (d, J=
7.1 Hz, 2H), 8.50–8.19 (m, 5H), 8.07 (d, J=8.6 Hz, 1H), 7.94 (d, J=
8.2 Hz, 2H), 7.54–7.41 (m, 6H), 7.41–7.30 (m, 6H), 7.30–7.19 (m,
2H), 7.19–7.11 (m, 2H), 7.07 (dd, J=2.1, 8.3 Hz, 1H), 6.79 (dd, J=
2.1, 8.6 Hz, 1H), 4.92 (d, J=5.9 Hz, 2H), 4.89 (d, J=5.8 Hz, 2H), 3.99
(s, 3H), 3.98 ppm (s, 3H); 13C NMR (126 MHz, [D6]DMSO): d=160.8,
155.8, 155.4, 153.51, 153.49, 153.1, 144.2, 141.7, 139.9, 139.8, 138.4,
138.1, 132.2, 130.3, 128.5, 127.0, 126.9, 126.7, 126.6, 126.5, 125.13,
125.08, 122.6, 122.4, 118.0, 115.6, 115.4, 114.8, 114.1, 113.1, 113.0,
112.9, 112.8, 56.1, 44.6, 44.5 ppm; HRMS-ESI: m/z [M+H]+ calcd for
C23H20ClN6O: 431.1387, found: 431.1400; HPLC purity: 97.8%.
2-(2-Amino-5-bromo-1H-benzo[d]imidazol-1-yl)-N-benzyl-8-me-
thoxyquinazolin-4-amine and 2-(2-Amino-6-bromo-1H-benzo[d]i-
midazol-1-yl)-N-benzyl-8-methoxyquinazolin-4-amine (~1:0.73)
(24): N-Benzyl-2-chloro-8-methoxyquinazolin-4-amine and 5-
bromo-1H-benzo[d]imidazol-2-amine were reacted according to
general procedure A to give 24, a white solid, as a mixture of re-
gioisomers (12 mg, 50%): 1H NMR (400 MHz, [D6]DMSO): d=9.30
(d, J=4.1 Hz, 2H), 8.53 (d, J=2.0 Hz, 1H), 8.27 (d, J=15.2 Hz, 4H),
7.95 (d, J=8.6 Hz, 1H), 7.86 (d, J=8.4 Hz, 2H), 7.38 (ddd, J=3.9,
7.2, 11.2 Hz, 6H), 7.28 (dt, J=6.3, 14.9 Hz, 6H), 7.23–7.09 (m, 4H),
7.02 (d, J=8.3 Hz, 1H), 6.83 (dd, J=2.0, 8.6 Hz, 1H), 4.84 (d, J=
5.9 Hz, 2H), 4.81 (d, J=5.8 Hz, 2H), 3.91 (s, 3H), 3.90 ppm (s, 3H);
13C NMR (126 MHz, [D6]DMSO): d=160.8, 160.7, 155.6, 155.3, 153.5,
153.5, 153.1, 144.7, 142.2, 139.9, 139.8, 138.4, 138.1, 132.7, 130.7,
128.5, 128.5, 127.0, 126.9, 126.7, 126.5, 125.2, 125.1, 120.8, 117.5,
116.9, 116.2, 116.0, 114.7, 114.1, 113.04, 113.03, 112.8, 112.8, 110.3,
56.1, 44.6, 44.5 ppm; HRMS-ESI: m/z [M+H]+ calcd for
C23H20BrN6O: 475.0882 and 477.0862 (
81Br), found: 477.0894; HPLC
purity: 95.5%.
2-(2-Amino-5-methyl-1H-benzo[d]imidazol-1-yl)-N-benzyl-8-me-
thoxyquinazolin-4-amine and 2-(2-Amino-6-methyl-1H-benzo[-
d]imidazol-1-yl)-N-benzyl-8-methoxyquinazolin-4-amine (~1:1)
(25): N-Benzyl-2-chloro-8-methoxyquinazolin-4-amine and 5-
methyl-1H-benzo[d]imidazol-2-amine were reacted according to
general procedure A to give 25, a white solid, as a mixture of re-
gioisomers (13.7 mg, 67%): 1H NMR (400 MHz, [D6]DMSO): d=9.22
(t, J=5.8 Hz, 2H), 8.13–7.97 (m, 5H), 7.94 (d, J=8.1 Hz, 1H), 7.84
(d, J=8.3 Hz, 2H), 7.36 (td, J=3.8, 7.9 Hz, 6H), 7.28 (td, J=5.1,
7.6 Hz, 6H), 7.18 (t, J=7.2 Hz, 2H), 6.94 (d, J=7.9 Hz, 1H), 6.88 (s,
1H), 6.76 (d, J=6.8 Hz, 1H), 6.54 (d, J=7.1 Hz, 1H), 4.90 (d, J=
5.9 Hz, 2H), 4.83 (d, J=5.8 Hz, 2H), 3.90 (s, 3H), 3.90 (s, 3H), 2.24
(d, J=7.5 Hz, 3H), 2.08 ppm (s, 3H); 13C NMR (101 MHz, [D6]DMSO):
d=160.9, 160.8, 154.8, 154.5, 153.5, 153.5, 153.4, 143.0, 140.6,
140.1, 140.1, 138.5, 138.4, 131.7, 131.3, 129.5, 128.48, 128.45, 127.4,
126.92, 126.88, 126.6, 126.5, 124.8, 124.7, 123.3, 119.5, 115.3, 115.1,
114.4, 114.2, 114.1, 112.9, 112.8, 112.69, 112.67, 56.1, 44.5, 44.4, 21.2,
21.1 ppm; HRMS-ESI : m/z [M+H]+ calcd for C24H23N6O: 411.1933,
found: 411.1959; HPLC purity: 93.2%.
2-(2-Amino-5-methoxy-1H-benzo[d]imidazol-1-yl)-N-benzyl-8-
methoxyquinazolin-4-amine and 2-(2-Amino-6-methoxy-1H-ben-
zo[d]imidazol-1-yl)-N-benzyl-8-methoxyquinazolin-4-amine (~
1:1) (26): N-Benzyl-2-chloro-8-methoxyquinazolin-4-amine and 5-
methoxy-1H-benzo[d]imidazol-2-amine were reacted according to
general procedure A to give 26, a white solid, as a mixture of re-
gioisomers (10.2 mg, 48%): 1H NMR (400 MHz, [D6]DMSOO): d=
9.21 (d, J=4.2 Hz, 2H), 8.11 (d, J=2.5 Hz, 3H), 7.97 (d, J=8.8 Hz,
1H), 7.91 (s, 2H), 7.84 (dd, J=4.8, 7.4 Hz, 2H), 7.36 (ddd, J=1.7,
5.9, 9.7 Hz, 6H), 7.28 (q, J=7.5 Hz, 6H), 7.19 (dd, J=3.4, 7.3 Hz,
2H), 6.98 (d, J=8.5 Hz, 1H), 6.65 (d, J=2.5 Hz, 1H), 6.59 (dd, J=
2.6, 8.5 Hz, 1H), 6.33 (dd, J=2.6, 8.8 Hz, 1H), 4.88 (d, J=5.8 Hz,
2H), 4.83 (d, J=5.8 Hz, 2H), 3.904 (s, 3H), 3.900 (s, 3H), 3.66 (s,
3H), 3.47 ppm (s, 3H); 13C NMR (101 MHz, [D6]DMSO): d=160.8,
160.7, 155.9, 155.3, 154.1, 153.6, 153.5, 153.4, 153.3, 153.2, 143.9,
140.2, 140.1, 138.5, 138.4, 136.7, 128.5, 128.5, 127.1, 127.0, 126.7,
124.9, 124.7, 115.0, 114.7, 114.1, 112.90, 112.87, 112.73, 112.69,
109.9, 105.4, 100.9, 99.6, 56.1, 55.2, 55.1, 44.53, 44.47 ppm; HRMS-
ESI : m/z [M+H]+ calcd for C24H23N6O2: 427.1882, found: 427.1910;
HPLC purity: 90.2%.
2-(2-Amino-4-fluoro-1H-benzo[d]imidazol-1-yl)-N-benzyl-8-me-
thoxyquinazolin-4-amine (27): N-Benzyl-2-chloro-8-methoxyquina-
zolin-4-amine and 4-fluoro-1H-benzo[d]imidazol-2-amine were re-
acted according to general procedure A to give 27 as a white solid
(5.3 mg, 51%): 1H NMR (500 MHz, [D6]DMSO): d=9.37 (t, J=5.9 Hz,
1H), 8.33 (s, 2H), 8.02–7.96 (m, 1H), 7.94 (d, J=7.6 Hz, 1H), 7.47 (t,
J=8.1 Hz, 1H), 7.43 (d, J=7.2 Hz, 2H), 7.40–7.32 (m, 3H), 7.25 (t,
J=7.3 Hz, 1H), 6.88 (dd, J=8.2, 9.9 Hz, 1H), 6.76 (td, J=5.2, 8.1 Hz,
1H), 4.90 (d, J=5.8 Hz, 2H), 3.98 ppm (s, 3H); 13C NMR (126 MHz,
[D6]DMSO): d=160.8, 154.9, 153.5, 153.2, 149.5, 139.8, 138.4, 134.3,
134.2, 128.5, 126.9, 126.6, 125.2, 118.7, 118.6, 114.1, 113.1, 112.8,
111.3, 108.8, 108.6, 56.1, 44.5 ppm; HRMS-ESI : m/z [M+H]+ calcd
for C23H20FN6O: 415.1683, found: 415.1709; HPLC purity: 98.8%.
2-(2-Amino-7-fluoro-1H-benzo[d]imidazol-1-yl)-N-benzyl-8-me-
thoxyquinazolin-4-amine (28): The regioisomer of 27 was isolated
by reversed-phase preparative HPLC from the above reaction mix-
ture to give 28 as a white solid (2.1 mg, 20%): 1H NMR (400 MHz,
[D6]DMSO): d=9.20 (s, 1H), 7.91 (d, J=7.5 Hz, 1H), 7.62 (s, 2H),
7.49 (t, J=8.1 Hz, 1H), 7.37 (d, J=7.3 Hz, 1H), 7.35–7.25 (m, 4H),
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7.23 (d, J=7.1 Hz, 1H), 7.13–7.02 (m, 2H), 6.85–6.75 (m, 1H), 4.85
(d, J=5.8 Hz, 2H), 3.96 ppm (s, 3H); 13C NMR (126 MHz,
[D6]DMSOO): d=160.8, 154.9, 153.5, 153.2, 149.5, 139.8, 138.4,
134.3, 134.2, 128.5, 126.9, 126.6, 125.2, 118.7, 118.6, 114.1, 113.1,
112.8, 111.3, 108.8, 108.6, 56.1, 44.5 ppm; HRMS-ESI : m/z [M+H]+
calcd for C23H20FN6O: 415.1683, found: 415.1709; HPLC purity:
96.8%.
2-(2-Amino-4-methyl-1H-benzo[d]imidazol-1-yl)-N-benzyl-8-me-
thoxyquinazolin-4-amine (29): N-Benzyl-2-chloro-8-methoxyquina-
zolin-4-amine and 4-methyl-1H-benzo[d]imidazol-2-amine were re-
acted according to general procedure A to give 29 as a white solid
(5.4 mg, 53%): 1H NMR (400 MHz, [D6]DMSO): d=9.23 (t, J=5.9 Hz,
1H), 8.11 (s, 2H), 7.94 (d, J=7.8 Hz, 1H), 7.85 (d, J=7.4 Hz, 1H),
7.42–7.33 (m, 3H), 7.28 (t, J=7.6 Hz, 3H), 7.17 (t, J=7.3 Hz, 1H),
6.79 (d, J=7.3 Hz, 1H), 6.64 (t, J=7.7 Hz, 1H), 4.84 (d, J=5.8 Hz,
2H), 3.91 (s, 3H), 2.30 ppm (s, 3H); 13C NMR (126 MHz, [D6]DMSO):
d=160.7, 154.2, 153.5, 153.5, 141.4, 140.0, 138.5, 130.9, 128.4,
126.9, 126.7, 124.8, 123.6, 123.2, 118.5, 114.1, 112.9, 112.7, 112.6,
56.1, 44.5, 16.4 ppm; HRMS-ESI : m/z [M+H]+ calcd for C24H23N6O:
411.1933, found: 411.1956; HPLC purity: 99.0%.
2-(2-Amino-5-fluoro-1H-benzo[d]imidazol-1-yl)-N-benzyl-8-me-
thoxyquinazolin-4-amine and 2-(2-Amino-6-fluoro-1H-benzo[d]i-
midazol-1-yl)-N-benzyl-8-methoxyquinazolin-4-amine (~1.1:1)
(30): N-Benzyl-2-chloro-8-methoxyquinazolin-4-amine and 5-fluoro-
1H-benzo[d]imidazol-2-amine were reacted according to general
procedure A to give 30, a white solid, as a mixture of regioisomers
(14.1 mg, 68%): 1H NMR (500 MHz, [D6]DMSO): d=9.44–9.31 (m,
2H), 8.34 (s, 2H), 8.18 (s, 2H), 8.13–8.04 (m, 2H), 7.93 (d, J=7.6 Hz,
2H), 7.51–7.40 (m, 6H), 7.40–7.30 (m, 6H), 7.25 (dt, J=5.4, 10.8 Hz,
2H), 7.10 (dd, J=5.1, 8.5 Hz, 1H), 6.96–6.83 (m, 2H), 6.64–6.55 (m,
1H), 4.89 (t, J=6.3 Hz, 4H), 3.98 (s, 3H), 3.97 ppm (s, 3H); 13C NMR
(126 MHz, [D6]DMSO): d=160.72, 160.70, 159.9, 158.0, 157.2, 156.0,
155.4, 155.2, 153.53, 153.47, 153.13, 153.08, 144.1, 144.0, 139.90,
139.04, 138.38, 138.17, 131.5, 131.4, 128.51, 128.49, 128.0, 127.0,
126.9, 126.6, 125.1, 124.9, 115.1, 115.0, 114.44, 114.37, 114.1, 113.02,
113.00, 112.8, 112.7, 109.2, 109.0, 104.9, 104.7, 102.7, 102.4, 101.2,
101.0, 56.08, 56.06, 44.6, 44.5 ppm; HRMS-ESI: m/z [M+H]+ calcd
for C23H20FN6O: 415.1683, found: 415.1689; HPLC purity: 98.8%.
2-(2H-Benzo[b][1,4]oxazin-4(3H)-yl)-N-benzyl-5,6-dimethylpyrimi-
din-4-amine (31): N-Benzyl-2-chloro-5,6-dimethylpyrimidin-4-amine
and 3,4-dihydro-2H-benzo[b][1,4]oxazine were reacted according to
general procedure A to give 31 as a brown oil (6.5 mg, 46%):
1H NMR (400 MHz, CDCl3): d=8.13–7.99 (m, 1H), 7.42–7.30 (m, 5H),
6.94–6.87 (m, 2H), 6.81–6.74 (m, 1H), 4.82 (s, 1H), 4.69 (d, J=
5.6 Hz, 2H), 4.31–4.26 (m, 2H), 4.29–4.23 (m, 2H), 2.35 (s, 3H),
2.01 ppm (s, 3H); 13C NMR (101 MHz, CDCl3): d=161.7, 160.9, 157.2,
145.9, 139.5, 128.6, 128.4, 127.5, 127.2, 124.0, 122.7, 119.5, 116.6,
101.8, 65.9, 45.3, 42.2, 22.2, 10.9 ppm; HRMS-ESI: m/z [M+H]+
calcd for C21H23N4O: 347.1872, found: 347.1872; HPLC purity:
100%.
2-(2H-Benzo[b][1,4]oxazin-4(3H)-yl)-N-benzylpyrimidin-4-amine
(32): N-Benzyl-2-chloropyrimidin-4-amine and 3,4-dihydro-2H-
benzo[b][1,4]oxazine were reacted according to general procedur-
e A to give 32 as a brown oil (20.0 mg, 69%): 1H NMR (400 MHz,
CDCl3): d=8.08–7.96 (m, 2H), 7.45–7.30 (m, 5H), 7.01–6.89 (m, 2H),
6.89–6.78 (m, 1H), 5.91 (d, J=5.8 Hz, 1H), 5.13 (s, 1H), 4.57 (d, J=
5.0 Hz, 2H), 4.35–4.27 (m, 2H), 4.27–4.17 ppm (m, 2H); 13C NMR
(101 MHz, CDCl3): d=162.6, 159.7, 156.2, 146.3, 138.5, 128.7, 127.8,
127.5, 127.4, 124.4, 123.6, 119.6, 116.8, 66.0, 45.3, 42.1 ppm; HRMS-
ESI : m/z [M+H]+ calcd for C19H19N4O: 319.1559, found: 319.1555;
HPLC purity: 100%.
2-((2-(2H-Benzo[b][1,4]oxazin-4(3H)-yl)-4-(benzylamino)quinazo-
lin-8-yl)oxy)ethanol (33): 2-(2H-Benzo[b][1,4]oxazin-4(3H)-yl)-4-
(benzylamino)quinazolin-8-ol and 2-chloroethanol were reacted ac-
cording to general procedure B to give 33 as a brown oil (3.7 mg,
33%): 1H NMR (400 MHz, CDCl3): d=8.05 (d, J=7.3 Hz, 1H), 7.39
(dd, J=5.9, 7.5 Hz, 6H), 7.20 (d, J=6.7 Hz, 1H), 7.12 (t, J=7.9 Hz,
1H), 6.99 (d, J=6.9 Hz, 1H), 6.97–6.91 (m, 1H), 6.84 (t, J=7.6 Hz,
1H), 4.84 (d, J=5.5 Hz, 2H), 4.34 (s, 4H), 4.29–4.18 (m, 2H), 3.92–
3.81 ppm (m, 2H); 13C NMR (101 MHz, CDCl3): d=159.8, 146.5,
138.2, 128.8, 127.8, 127.6, 127.4, 124.4, 124.1, 122.4, 119.5, 118.6,
117.0, 114.9, 112.2, 73.6, 66.1, 60.8, 45.4, 42.5 ppm; HRMS-ESI: m/z
[M+H]+ calcd for C25H25N4O3: 429.1927, found: 429.1925; HPLC
purity: 100%.
2-(2H-Benzo[b][1,4]oxazin-4(3H)-yl)-N-benzyl-8-(2-methoxyethox-
y)quinazolin-4-amine (34): 2-(2H-Benzo[b][1,4]oxazin-4(3H)-yl)-4-
(benzylamino)quinazolin-8-ol and 1-chloro-2-methoxyethane were
reacted according to general procedure B to give 34 as a brown
oil (3.6 mg, 27%): 1H NMR (400 MHz, CDCl3): d=8.28 (d, J=7.7 Hz,
1H), 7.40–7.39 (m, 4H), 7.37–7.32 (m, 1H), 7.21–719 (m, 1H), 7.13–
7.09 (m, 2H), 6.99–6.88 (m, 2H), 6.83–6.79 (m, 1H), 5.86 (br s, 1H),
4.83 (d, J=5.4 Hz, 2H), 4.45–4.38 (m, 2H), 4.38–4.27 (m, 4H), 3.97–
3.88 (m, 2H), 3.56 ppm (s, 3H); 13C NMR (126 MHz, CDCl3): d=
159.7, 156.0, 153.2, 146.2, 143.9, 138.4, 128.8, 128.1, 127.7, 127.6,
124.5, 123.2, 121.9, 119.4, 116.6, 114.0, 113.0, 111.9, 71.1, 68.8, 66.1,
59.5, 45.4, 42.1, 29.7 ppm; HRMS-ESI: m/z [M+H]+ calcd for
C26H27N4O3: 443.2083, found: 443.2088; HPLC purity: 98.0%.
2-(2H-Benzo[b][1,4]oxazin-4(3H)-yl)-N-benzyl-8-(2-(diethylami-
no)ethoxy)quinazolin-4-amine (35): 2-(2H-Benzo[b][1,4]oxazin-
4(3H)-yl)-4-(benzylamino)quinazolin-8-ol and 2-bromo-N,N-diethyle-
thanamine hydrochloride were reacted according to general proce-
dure B to give 35 as a brown oil (4.1 mg, 64%): 1H NMR (400 MHz,
CDCl3): d=7.98–7.79 (m, 1H), 7.31–7.22 (m, 6H), 7.05 (s, 2H), 6.85
(s, 2H), 6.70 (s, 1H), 4.75 (d, J=5.5, 2H), 4.58 (s, 2H), 4.21 (s, 4H),
3.48 (s, 2H), 3.21 (d, J=7.3, 4H), 1.32 ppm (t, J=7.3, 6H); HRMS-
ESI : m/z [M+H]+ calcd for C29H34N5O2: 484.2713 found: 484.2712;
HPLC purity: 68.2%.
2-(2H-Benzo[b][1,4]oxazin-4(3H)-yl)-N-benzyl-8-(4-methoxyphe-
nyl)quinazolin-4-amine (36): A mixture of 2-(2H-benzo[b]-
[1,4]oxazin-4(3H)-yl)-N-benzyl-8-bromoquinazolin-4-amine (12.0 mg,
26.8 mmol), palladium acetate (0.6 mg, 2.7 mmol), [1,1’-biphenyl]-2-
yldicyclohexylphosphine (1.9 mg, 5.4 mmol), 4-methoxyphenylbor-
onic acid (6.1 mg, 40.2 mmol) and potassium fluoride (4.7 mg,
80.5 mmol) in THF (0.5 mL) was heated at 50 8C for 16 h. The mix-
ture was diluted with EtOAc and washed with H2O. The organic
phase was concentrated and purified by silica gel chromatography
to give 36 as a brown solid (12 mg, 94%): Rf=0.5 (CH2Cl2/CH3OH,
1:9) ; 1H NMR (400 MHz, CDCl3): d=8.17–8.09 (m, 1H), 7.75–7.69 (m,
2H), 7.68 (dd, J=1.4, 7.3 Hz, 1H), 7.56 (dd, J=1.3, 8.2 Hz, 1H), 7.40
(dd, J=1.9, 3.5 Hz, 4H), 7.39–7.32 (m, 1H), 7.28–7.21 (m, 1H), 7.07–
7.00 (m, 2H), 6.92 (dtd, J=1.6, 8.1, 9.9 Hz, 2H), 6.77–6.70 (m, 1H),
5.94 (s, 1H), 4.85 (t, J=5.3 Hz, 2H), 4.33–4.25 (m, 4H), 3.92 ppm (s,
3H); 13C NMR (101 MHz, CDCl3): d=160.1, 158.8, 156.1, 149.5,
146.2, 138.6, 137.6, 133.1, 131.9, 131.6, 128.8, 128.2, 127.7, 127.6,
125.1, 123.2, 121.9, 119.5, 119.4, 116.5, 113.2, 111.6, 66.1, 55.4, 45.5,
42.1 ppm; 89%): HRMS-ESI: m/z [M+H]+ calcd for C30H27N4O2:
475.2134, found: 475.2135; HPLC purity: 92.9%.
2-(2H-Benzo[b][1,4]oxazin-4(3H)-yl)-N-benzyl-8-butoxyquinazo-
lin-4-amine (37): N-Benzyl-8-butoxy-2-chloroquinazolin-4-amine
and 3,4-dihydro-2H-benzo[b][1,4]oxazine were reacted according to
general procedure A to give 37 as a brown oil (4.9 mg, 61%):
1H NMR (400 MHz, CDCl3): d=8.37 (d, J=8.2 Hz, 1H), 7.47–7.31 (m,
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5H), 7.20–7.07 (m, 2H), 7.04 (dd, J=1.5, 7.5 Hz, 1H), 7.00–6.89 (m,
2H), 6.89–6.77 (m, 1H), 5.85 (s, 1H), 4.84 (d, J=5.4 Hz, 2H), 4.48–
4.38 (m, 2H), 4.35–4.32 (m, 2H), 4.15 (t, J=6.5 Hz, 2H), 2.04–1.89
(m, 2H), 1.72–1.62 (m, 2H), 1.08 ppm (t, J=7.4 Hz, 3H); 13C NMR
(101 MHz, CDCl3): d=159.7, 155.9, 153.6, 146.2, 143.7, 138.5, 128.8,
128.3, 127.7, 127.6, 124.4, 123.1, 121.9, 119.5, 116.6, 112.7, 112.1,
111.8, 68.6, 66.1, 45.4, 42.1, 31.4, 19.4, 14.0 ppm; HRMS-ESI : m/z
[M+H]+ calcd for C27H29N4O2: 441.2291, found: 441.2296; HPLC
purity: 100%.
2-(2H-Benzo[b][1,4]oxazin-4(3H)-yl)-N-benzyl-8-methoxyquinazo-
lin-4-amine (38): N-Benzyl-2-chloro-8-methoxyquinazolin-4-amine
and 3,4-dihydro-2H-benzo[b][1,4]oxazine were reacted according to
general procedure A to give 38 as a brown oil (7.1 mg, 53%):
1H NMR (400 MHz, CDCl3): d=8.21–8.08 (m, 1H), 7.46–7.31 (m, 5H),
7.18 7.11 (m, 2H), 7.05 (dd, J=1.6, 7.3 Hz, 1H), 6.99–6.88 (m, 2H),
6.80 (ddd, J=2.3, 6.5, 8.7 Hz, 1H), 5.86 (s, 1H), 4.83 (d, J=5.5 Hz,
2H), 4.50–4.40 (m, 2H), 4.40–4.29 (m, 2H), 4.03 ppm (s, 3H);
13C NMR (101 MHz, CDCl3): d=159.7, 156.2, 153.9, 146.2, 143.6,
138.5, 128.8, 128.1, 127.8, 127.6, 124.3, 123.2, 121.9, 119.4, 116.7,
112.3, 111.8, 111.4, 66.2, 56.1, 45.4, 42.2 ppm; HRMS-ESI : m/z [M+
H]+ calcd for C24H23N4O2: 399.1821, found: 399.1824; HPLC purity:
100%.
2-(2H-Benzo[b][1,4]oxazin-4(3H)-yl)-N-(4-fluorobenzyl)-8-methox-
yquinazolin-4-amine (40): 2-Chloro-N-(4-fluorobenzyl)-8-methoxy-
quinazolin-4-amine and 3,4-dihydro-2H-benzo[b][1,4]oxazine were
reacted according to general procedure A to give 40 as a brown
oil (2.9 mg, 22%): 1H NMR (400 MHz, CDCl3): d=8.12–7.87 (m, 1H),
7.25 (br s, 2H), 7.14–7.02 (m, 2H), 6.98–6.93 (m, 2H), 6.84 (br s, 2H),
6.78–6.56 (m, 1H), 5.89–5.66 (m, 1H), 4.69 (br s, 2H), 4.32 (br s, 2H),
4.24 (br s, 2H), 3.92 ppm (s, 3H); 13C NMR (126 MHz, CDCl3) d=
163.2, 161.2, 159.7, 134.2, 129.5, 124.4, 123.3, 122.0, 119.4, 116.7,
115.6, 115.5, 112.3, 111.7, 111.4, 66.2, 56.2, 44.6, 42.2, 29.7 ppm;
HRMS-ESI : m/z [M+H]+ calcd for C24H22FN4O2: 417.1727, found:
417.1726; HPLC purity: 98.8%.
2-(2H-Benzo[b][1,4]oxazin-4(3H)-yl)-8-methoxy-N-(thiophen-2-yl-
methyl)quinazolin-4-amine (41): 2-Chloro-8-methoxy-N-(thiophen-
2-ylmethyl)quinazolin-4-amine and 3,4-dihydro-2H-benzo[b]-
[1,4]oxazine were reacted according to general procedure A to
give 41 as a brown oil (15.9 mg, 80%): 1H NMR (400 MHz, CDCl3):
d=8.25 (dd, J=1.4, 8.2 Hz, 1H), 7.27 (dd, J=1.3, 5.1 Hz, 1H), 7.19–
7.09 (m, 2H), 7.08–7.02 (m, 2H), 6.99 (ddd, J=2.5, 4.1, 8.1 Hz, 1H),
6.95 (dd, J=1.8, 4.0 Hz, 1H), 6.93–6.86 (m, 1H), 5.90 (s, 1H), 4.98
(d, J=5.1 Hz, 2H), 4.47 (dd, J=3.6, 5.3 Hz, 2H), 4.37 (dd, J=3.6,
5.3 Hz, 2H), 4.02 ppm (s, 3H); 13C NMR (101 MHz, CDCl3): d=159.3,
156.1, 153.9, 146.2, 143.6, 141.2, 128.1, 126.9, 126.2, 125.4, 124.4,
123.3, 122.0, 119.5, 116.7, 112.4, 111.7, 111.5, 66.2, 56.1, 42.3,
40.2 ppm; HRMS-ESI: m/z [M+H]+ calcd for C22H21N4O2S: 405.1385,
found: 405.1383; HPLC purity: 96.6%.
2-(2H-Benzo[b][1,4]oxazin-4(3H)-yl)-N-(cyclohexylmethyl)-8-me-
thoxyquinazolin-4-amine (42): 2-Chloro-N-(cyclohexylmethyl)-8-
methoxyquinazolin-4-amine and 3,4-dihydro-2H-benzo[b]-
[1,4]oxazine were reacted according to general procedure A to
give 42 as a brown oil (13.6 mg, 69%): 1H NMR (400 MHz, CDCl3):
d=8.26 (dd, J=1.4, 8.1 Hz, 1H), 7.20–7.09 (m, 2H), 7.03 (dd, J=1.9,
7.1 Hz, 1H), 7.01–6.86 (m, 3H), 5.69 (s, 1H), 4.46 (dd, J=3.6, 5.2 Hz,
2H), 4.37 (dd, J=3.6, 5.2 Hz, 2H), 4.02 (s, 3H), 3.54–3.42 (m, 2H),
187–1.71 (m, 6H), 1.40–1.13 (m, 4H), 1.04 ppm (q, J=12.0 Hz, 2H);
13C NMR (101 MHz, CDCl3): d=160.0, 156.4, 153.9, 146.2, 143.4,
128.2, 124.4, 123.1, 121.7, 119.3, 116.7, 112.2, 111.9, 111.2, 66.2, 56.1,
47.6, 42.2, 37.8, 31.1, 26.5, 25.9 ppm; HRMS-ESI : m/z [M+H]+ calcd
for C24H29N4O2: 405.2291, found: 405.2289; HPLC purity: 95.0%.
2-(((2-(2H-Benzo[b][1,4]oxazin-4(3H)-yl)-8-methoxyquinazolin-4-
yl)amino)methyl)phenol (43): 2-(((2-Chloro-8-methoxyquinazolin-
4-yl)amino)methyl)phenol and 3,4-dihydro-2H-benzo[b][1,4]oxazine
were reacted according to general procedure A to give 43 as
a brown solid (11.0 mg, 51%): 1H NMR (400 MHz, CDCl3): d=8.91
(br s, 1H), 7.97 (br s, 1H), 7.14–7.04 (m, 3H), 7.01 (t, J=7.9 Hz, 1H),
6.93 (d, J=8.8 Hz, 1H), 6.91–6.85 (m, 2H), 6.82 (t, J=7.3 Hz, 1H),
6.73 (t, J=7.2 Hz, 2H), 4.68 (br s, 2H), 4.30 (s, 4H), 3.87 ppm (s,
3H); 13C NMR (101 MHz, CDCl3): d=159.9, 155.8, 146.3, 130.8,
129.9, 124.0, 122.8, 119.9, 119.7, 117.4, 117.2, 112.6, 112.1, 111.7,
66.0, 56.1, 43.1, 42.0 ppm; HRMS-ESI: m/z [M+H]+ calcd for
C24H23N4O3: 415.1770, found: 415.1763; HPLC purity: 100%.
Acknowledgements
We thank B. E. Nordin and M. P. Patricelli (ActivX Biosciences La
Jolla, CA, USA) for analyzing the ACJI-47 positive control free of
charge in the kinase profiling experiments. Ki determinations and
receptor binding profiles were generously provided by the Nation-
al Institute of Mental Health’s Psychoactive Drug Screening Pro-
gram, Contract no. HHSN-271-2008-00025-C (NIMH PDSP). The
NIMH PDSP is Directed by Bryan L. Roth, MD PhD (University of
North Carolina, Chapel Hill, NC, USA) and Project Officer Jamie
Driscol (NIMH, Bethesda MD, USA). The NCI 60-cell-line screen
was performed by the Developmental Therapeutics Program at
the NCI. We thank Jeffrey Aub (University of Kansas, Lawrence,
KS, USA) for helpful discussions, P. Porubsky (University of Kansas)
for compound management, Ben Neuenswander (University of
Kansas) for compound purification and high-resolution mass de-
termination, Justin Douglas and Sarah Neuenswander (University
of Kansas) for NMR assistance, R. Weinberg (Massachusetts Insti-
tute of Technology, Cambridge, MA, USA) via H. Chang (Stanford
University, CA, USA) for providing PHMLEB and PHMLER cells,
K. S. Osthoff (Eberhard Karls University, Tbingen, Germany) via
G. M. Cohen (University of Leicester, UK) for caspase 9/ cells,
G. Salvesen (Sanford-Burnham Medical Research Institute) for
caspase 8/ cells, and H. Park, R. Oania, and D. Shimoda for
technical assistance. This work was supported by a grant from
the NIH Molecular Libraries Probe Production Centers Network to
Jeffrey Aub (PI) (5U54HG005031). R.J.D. and T.-F.C. were support-
ed by the Howard Hughes Medical Institute, of which R.J.D. is an
Investigator.
Keywords: AAA ATPase · autophagy · cancer · structure–
activity relationships · ubiquitin proteasome
[1] G. Giaever et al. , Nature 2002, 418, 387–391.
[2] J. M. Mller, K. Deinhardt, I. Rosewell, G. Warren, D. T. Shima, Biochem.
Biophys. Res. Commun. 2007, 354, 459–465.
[3] H. Kondo, C. Rabouille, R. Newman, T. P. Levine, D. Pappin, P. Freemont,
G. Warren, Nature 1997, 388, 75–78.
[4] R. Golbik, A. N. Lupas, K. K. Koretke, W. Baumeister, J. Peters, Biol. Chem.
1999, 380, 1049–1062.
[5] C. Rabouille, T. P. Levine, J. M. Peters, G. Warren, Cell 1995, 82, 905–914.
[6] Y. Ye, H. H. Meyer, T. A. Rapoport, Nature 2001, 414, 652–656.
[7] P. C. Janiesch, J. Kim, J. Mouysset, R. Barikbin, H. Lochmuller, G. Cassata,
S. Krause, T. Hoppe, Nat. Cell Biol. 2007, 9, 379–390.
[8] K. Cao, R. Nakajima, H. H. Meyer, Y. Zheng, Cell 2003, 115, 355–367.
 2013 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemMedChem 2013, 8, 297 – 312 311
CHEMMEDCHEM
FULL PAPERS www.chemmedchem.org
[9] C. Boyault, Y. Zhang, S. Fritah, C. Caron, B. Gilquin, S. H. Kwon, C. Garri-
do, T. P. Yao, C. Vourc’h, P. Matthias, S. Khochbin, Genes Dev. 2007, 21,
2172–2181.
[10] J. S. Ju, R. A. Fuentealba, S. E. Miller, E. Jackson, D. Piwnica-Worms, R. H.
Baloh, C. C. Weihl, J. Cell Biol. 2009, 187, 875–888.
[11] E. Tresse, F. A. Salomons, J. Vesa, L. C. Bott, V. Kimonis, T. P. Yao, N. P.
Dantuma, J. P. Taylor, Autophagy 2010, 6, 217–227.
[12] H. H. Meyer, J. G. Shorter, J. Seemann, D. Pappin, G. A. Warren, EMBO J.
2000, 19, 2181–2192.
[13] C. Schuberth, A. Buchberger, Cell. Mol. Life Sci. 2008, 65, 2360–2371.
[14] G. Alexandru, J. Graumann, G. T. Smith, N. J. Kolawa, R. Fang, R. J. De-
shaies, Cell 2008, 134, 804–816.
[15] D. Ritz, M. Vuk, P. Kirchner, M. Bug, S. Schutz, A. Hayer, S. Bremer, C.
Lusk, R. H. Baloh, H. Lee, T. Glatter, M. Gstaiger, R. Aebersold, C. C. Weihl,
H. Meyer, Nat. Cell Biol. 2011, 13, 1116–1123.
[16] T. Huyton, V. E. Pye, L. C. Briggs, T. C. Flynn, F. Beuron, H. Kondo, J. Ma,
X. Zhang, P. S. Freemont, J. Struct. Biol. 2003, 144, 337–348.
[17] B. DeLaBarre, A. T. Brunger, Nat. Struct. Biol. 2003, 10, 856–863.
[18] Q. Wang, C. Song, C. C. Li, Biochem. Biophys. Res. Commun. 2003, 300,
253–260.
[19] C. Song, Q. Wang, C. C. Li, J. Biol. Chem. 2003, 278, 3648–3655.
[20] Y. Ye, H. H. Meyer, T. A. Rapoport, J. Cell Biol. 2003, 162, 71–84.
[21] S. Nishikori, M. Esaki, K. Yamanaka, S. Sugimoto, T. Ogura, J. Biol. Chem.
2011, 286, 15815–15820.
[22] T.-F. Chou, S. J. Brown, D. Minond, B. E. Nordin, K. Li, A. C. Jones, P.
Chase, P. R. Porubsky, B. M. Stoltz, F. J. Schoenen, M. P. Patricelli, P.
Hodder, H. Rosen, R. J. Deshaies, Proc. Natl. Acad. Sci. USA 2011, 108,
4834–4839.
[23] T.-F. Chou, R. J. Deshaies, J. Biol. Chem. 2011, 286, 16546–16554.
[24] B. DeLaBarre, J. C. Christianson, R. R. Kopito, A. T. Brunger, Mol. Cell
2006, 22, 451–462.
[25] S. Luo, D. C. Rubinsztein, Cell Death Differ. 2010, 17, 268–277.
[26] A. Degterev, Z. Huang, M. Boyce, Y. Li, P. Jagtap, N. Mizushima, G. D.
Cuny, T. J. Mitchison, M. A. Moskowitz, J. Yuan, Nat. Chem. Biol. 2005, 1,
112–119.
[27] B. Elenbaas, L. Spirio, F. Koerner, M. D. Fleming, D. B. Zimonjic, J. L. Do-
naher, N. C. Popescu, W. C. Hahn, R. A. Weinberg, Genes Dev. 2001, 15,
50–65.
[28] J. A. Blair, D. Rauh, C. Kung, C. H. Yun, Q. W. Fan, H. Rode, C. Zhang,
M. J. Eck, W. A. Weiss, K. M. Shokat, Nat. Chem. Biol. 2007, 3, 229–238.
[29] M. P. Patricelli, A. K. Szardenings, M. Liyanage, T. K. Nomanbohoy, M. Wu,
H. Weissig, A. Aban, D. Chun, S. Tanner, J. W. Kozarich, Biochemistry
2007, 46, 350–358.
[30] A. C. Bishop, K. Shah, Y. Liu, L. Witucki, C. Kung, K. M. Shokat, Curr. Biol.
1998, 8, 257–266.
[31] T.-F. Chou, R. J. Deshaies, Autophagy 2011, 7, 1091–1092.
[32] A. Griciuc, L. Aron, M. J. Roux, R. Klein, A. Giangrande, M. Ueffing, PLoS
Genet. 2010, 6, e1001075.
[33] C. W. Valle, T. Min, M. Bodas, S. Mazur, S. Begum, D. Tang, N. Vij, PLoS
One 2011, 6, e29073.
[34] S. L. McGovern, E. Caselli, N. Grigorieff, B. K. Shoichet, J. Med. Chem.
2002, 45, 1712–1722.
[35] N. P. Dantuma, K. Lindsten, R. Glas, M. Jellne, M. G. Masucci, Nat. Bio-
technol. 2000, 18, 538–543.
[36] E. A. Kimbrel, T. N. Davis, J. E. Bradner, A. L. Kung, Mol. Imaging 2009, 8,
141–147.
Received: November 8, 2012
Revised: December 7, 2012
Published online on January 11, 2013
 2013 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemMedChem 2013, 8, 297 – 312 312
CHEMMEDCHEM
FULL PAPERS www.chemmedchem.org
